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Abstract 
The Gi-coupled, ADP-activated P2Y12 receptor is well-characterised as playing a key role 
in platelet activation via crosstalk with P2Y1. A crucial aspect of P2Y12-P2Y1 crosstalk in 
platelets involves ADP-induced intracellular calcium (Ca2+) mobilisation, however there 
is limited knowledge on the role of P2Y12 in ADP-evoked Ca2+ responses in other blood 
cells. Here, we investigate the expression of P2Y12 in human monocytes and the 
contribution of P2Y12 in THP-1 ADP-evoked Ca2+ responses. 
  
RT-PCR analysis showed that all ADP-binding P2Y receptors were expressed in THP-1 
monocytes at the mRNA level, with P2Y12 expressed in CD14+ primary monocytes. P2Y12 
protein was found to be expressed in THP-1 cells, using immunocytochemistry. ADP-
evoked Ca2+ responses in fura-2-loaded THP-1 cells were completely abolished by a 
sarco/endoplasmic reticulum Ca2+-ATPase inhibitor, and by a phospholipase C inhibitor, 
indicating that these Ca2+ responses are mediated through GPCRs. Ca2+ responses 
induced by ADP were significantly reduced by the P2Y12 inhibitors ticagrelor and PSB-
0739 and by the P2Y6 antagonist MRS2578, but not by P2Y1 or P2Y13 inhibitors. Using 
P2Y6-overexpressing astrocytomas, ticagrelor was found to be selective for P2Y12 over 
P2Y6 at the concentrations used here, although PSB-0739 was not. ADP-induced Ca2+ 
responses were significantly decreased in THP-1 cells with siRNA-mediated P2Y12 
knockdown. Pertussis toxin-mediated Gi inhibition caused a significant reduction in 
ADP-induced Ca2+ responses, as did the PI3K inhibitor LY294002. Use of the adenylate 
cyclase inhibitor SQ22536 had no effect on sole ADP-evoked Ca2+ responses, but caused 
significant recovery of Ca2+ responses inhibited by P2Y12 antagonists. 
 
The results from this study suggest that Ca2+ responses evoked by ADP in THP-1 cells 
are dependent on both P2Y12 and P2Y6 activation, with P2Y12 positively modulating Gq-
coupled P2Y6-mediated Ca2+ responses via adenylate cyclase inhibition and PI3K 
activation. Overall, this investigation reveals a new role for P2Y12 in non-platelet Ca2+ 
responses, and contributes to our understanding of how monocytes function in health 
and disease. 
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Chapter 1 – Introduction 
 
1.1 - Monocytes 
1.1.1 - Monocytes – Background 
Derivation, development & subtypes 
Known as one of the ‘professional’ phagocytes, monocytes are a type of leukocyte that 
exists in all vertebrates and amount to 10% of the nucleated cells in human blood (van 
Furth and Sluiter, 1986). Monocytes originate from primary lymphoid organs that include 
the bone marrow and the foetal liver, where they derive from the common myeloid 
progenitor cell (Ginhoux and Jung, 2014). Monocytes undergo apoptosis in the absence 
of appropriate stimuli, with pro-inflammatory cytokines such as IL-1β and TNF-α proving 
fundamental in preventing monocyte apoptosis (Mangan and Wahl, 1991). This indicates 
that monocyte viability is modulated by the presence of inflammatory markers (Mangan 
and Wahl, 1991). 
 
There are several subsets of human monocyte population, which are essentially based on 
expression of CD14 and CD16 molecules. Some of the main sub-populations include: the 
classical subset (high CD14 expression, no CD16 expression), the non-classical subset 
(low CD14 expression, high CD16 expression) and the intermediate subset (high CD14 
expression, low CD16 expression) (Wong et al., 2012). The subpopulations of monocytes 
have been shown to give rise to varying physiological effects, including differential 
cytokine production (Frankenburger et al., 1996) and antigen processing (Wong et al., 
2011) between the different monocyte subtypes. 
 
Morphology & physiological function 
Monocytes are spherical in shape and feature distinctive bean-shaped and single-lobed 
nuclei, and are the largest of all leukocytes. The cytoplasm contains dispersed granules, 
and many mitochondria, microfilaments and microtubules (Kaushansky and Williams, 
2010).  
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Monocytes constitutively circulate in the bloodstream and play a key role in immune 
surveillance whereby they migrate from the bloodstream to sites of infection and 
inflammation, where they are capable of differentiating into macrophages and dendritic 
cells (Serbina et al., 2008), thus forming an essential role in the immune system. In 
response to injury or infection, monocytes and their progeny facilitate innate immune 
defence via phagocytosis and cytokine production, but they can also activate the 
adaptive immune system through antigen uptake and presentation, providing a 
comprehensive immune response. It has long been thought that monocytes also 
continually replenish tissue-based dendritic cell and macrophage populations in the 
steady state, but novel experimental methods, including Cre–loxP-based fate-mapping 
systems, for example (Yona et al., 2013), have demonstrated that most tissue 
macrophage populations do not derive from monocytes (Hashimoto et al., 2013).  
 
CC-chemokine ligand 2 (CCL2) is a chemokine that binds to the CCR2 receptor and is 
released from cells activated during innate immune responses to a variety of microbial 
molecules (Tsou et al., 2007), and indeed a number of different infections cause an 
increased circulating CCL2 level. CCL2 is fundamental to the recruitment of monocytes 
to sites of infection, and furthermore, murine models have shown that CCL2- and/or 
CCR2-deficient mice have reduced monocyte recruitment in response to infections with 
Listeria monocytogenes (Kurihara et al., 1997), Toxoplasma gondii (Dunay et al., 2008) 
and several fungal (Osterholzer et al., 2009) and viral (Dawson et al., 2000. Lim et al., 
2010) infections.  
 
1.1.2 - Monocytes – Roles in human disease 
Atherosclerosis 
In addition to their beneficial and crucial inflammatory role for the innate immune 
system, monocytes also heavily contribute to the development of atherosclerosis, an 
inflammatory disease which is the leading cause of cardiovascular disease. Figure A 
illustrates the role of monocytes in atherosclerosis together with the description in this 
section. Monocytes are directly involved in the early stages of atherosclerosis 
development through recruitment to the arterial endothelium via CCL2-mediated 
chemotaxis, whereby they undergo endothelial adhesion, ‘rolling’, and subsequent 
migration (Figure A – 1) into the intima (Galkina and Ley, 2009). Mice lacking the CCL2 
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protein, or its receptor CCR2, developed much smaller atherosclerotic lesions (Gu et al., 
1998. Boring et al., 1998), emphasising the crucial role of the CCL2/CCR2 interaction in 
monocyte recruitment in atherosclerosis. 
 
In the intima, monocytes differentiate into macrophages, which accrue oxidised low-
density lipoprotein (oxLDL) and other lipids through their scavenger receptors (Figure 
A – 2), subsequently forming an early-stage plaque (Galkina and Ley, 2009). 
 
Figure A – Monocytes in the initiation and development of atherosclerosis 
The following provides a brief summary of the contribution of monocytes and their 
derivatives in atherosclerosis, with more detail provided in-text. Endothelial cells are 
activated upon initial injury, mediating the rolling and transmigration of recruited 
monocytes (1), which then differentiate into macrophages or dendritic cells. 
Macrophages consume lipoproteins (2), leading to fatty streak formation, with such 
macrophages enduring apoptosis, thus contributing to the destabilising necrotic core 
(3). Further progression of the plaque is facilitated through further recruitment of 
monocytes via inflammatory cytokine release (4). The schematic diagram was taken 
from Heine et al., (2012) and annotated. 
 
1. 
2. 
3. 
4. 
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Apolipoprotein E (apoE) is a glycoprotein that is essential in lipid transport and 
metabolism, and apoE-deficient mice provide a useful model for studying 
atherosclerosis as such mice have impaired plasma lipid clearance and subsequently 
rapidly develop atherosclerotic lesions (Kolovou et al., 2008). Studies have shown that 
apoE-deficient, hypercholesteraemic mice fed on a high-fat diet exhibited a dramatic 
increase in inflammatory monocytes, which were shown to adhere to an activated 
endothelium, infiltrate lesions, and become lesional macrophages (Swirski et al., 2007). 
Statin-induced cholesterol reduction caused a decrease in the number of inflammatory 
monocytes and consequently a reduction in lesion formation, therefore highlighting the 
level of monocyte recruitment during atherosclerosis (Swirski et al., 2007). 
 
Macrophages containing oxLDL become ‘foam cells’ and undergo apoptosis and 
necrosis, resulting in the progression of the atherosclerotic plaque, with accumulation 
of necrotic tissue, deposition of collagen and migration of smooth muscle also following 
(Figure A – 3) (Pamukcu et al., 2010). An inflammatory process is then established, 
with activated monocytes containing a higher number of toll-like receptors and 
releasing an excessive amount of inflammatory cytokines. This causes further 
transendothelial migration of monocytes to the plaque environment (Figure A – 4), 
consequently giving rise to plaque growth and destabilisation (Jaipersad et al., 2014).  
 
The instability of an atherosclerotic plaque is a high contributor to the chance of a 
thrombotic event, with approximately 75% of acute coronary events caused by the 
volatility of the responsible plaque (Jaipersad et al., 2014). When a plaque becomes 
structurally unstable, it is more likely to rupture, exposing and releasing lipids and 
tissue factor, which in turn activate the coagulation cascade, causing thrombus 
formation and potentially resulting in a myocardial infarction.  
 
The excessive release of inflammatory mediators by monocytes, such as IL-1β, IL-6 and 
TNF-α, contributes to the instability of an atheromatous plaque, not only by further 
recruitment of inflammatory cells, but also by contributing to neovascularisation 
(Shantsila and Lip, 2009). Activated monocytes produce matrix metalloproteinases 
(MMPs) (Shantsila and Lip, 2009), which allow vessel growth in neovascularisation, 
which is associated with plaque rupture (Kumamoto, 1995).  
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As described here, monocytes greatly participate in the pathology of atherosclerosis. 
From their initial recruitment, adhesion and migration across the endothelium, to 
differentiating into macrophages/foam cells, to contributing to plaque instability and 
therefore rupture, monocytes are involved in many stages of atherosclerosis. Further 
studies into how monocytes elicit such functions would undoubtedly be of great value 
due to their involvement in the pathological process of a leading cause of cardiovascular 
disease.  
 
Liver fibrosis 
Liver fibrosis occurs when type-I collagen is deposited to the extracellular space upon 
damage caused by, for example, chronic alcoholism or hepatitis B infection, which 
affects the functionality of the liver (Heymann, et al., 2009). It has been indicated in a 
mouse model of liver fibrosis that inflammatory monocytes contribute to the fibrosis 
progression by infiltrating the liver and activating collagen-producing cells, hepatic 
stellate cells, by releasing cytokines such as TGF-β (Karlmark et al., 2009). CCR2-
deficient mice exhibited reduced fibrosis compared to the control, which is suggested to 
be due to a decrease in inflammatory monocyte migration into the liver (Karlmark et al., 
2009). Additionally, CX3CR1-knockout mice demonstrated a more severe fibrosis 
phenotype owing to higher numbers of infiltrating inflammatory monocytes, indicating 
that the fractalkine receptor CX₃CR1 is protective in this case through the control of 
intrahepatic monocyte survival and differentiation (Karlmark et al., 2010). It is 
therefore evident that invading inflammatory monocytes contribute to the development 
of liver fibrosis. However, differentiation of infiltrating monocytes to macrophages in 
the liver leads to production of matrix metalloproteinases that contribute to a 
regression of fibrosis through breakdown of type-I collagen (Heymann, et al., 2009). 
Thus, monocytes cause progression of liver fibrosis during the early phases of the 
disease, but subsequently promote regression at later stages.  
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Cancer progression 
Recent findings indicate a role for monocytes in carcinogenesis and metastasis of 
cancerous tumours. Myeloid-derived suppressor cells (MDSCs) are indicated to 
contribute to cancer progression through the promotion of angiogenesis and metastasis, 
but also via inhibition of anti-tumour immune activity (Monu and Frey, 2012). It is 
suggested that MDSCs derived from monocytes release IL-10, consequently reducing the 
anti-tumour functions of T-cells (Karlmark et al., 2012). 
Moreover, a chemical-induced model of carcinogenesis revealed that histamine 
deficiency promotes carcinogenesis, which is coupled with infiltration of inflammatory 
monocytes (Yang et al., 2010). Inflammatory monocytes have been shown to infiltrate 
mammary tumours in mice, produce vascular endothelial growth factor, and 
subsequently promote metastasis of the tumour to the lung (Qian et al., 2011). 
Inhibition of CCL2 signalling, a major monocyte chemoattractant, blocked the 
recruitment of inflammatory monocytes and reduced metastasis, prolonging the 
survival of the mice (Qian et al., 2011). These findings, which include studies in vivo, 
indicate that monocytes have a major part to play in different stages of tumour 
progression.  
 
It is evident that monocytes are crucial cells in human health and disease, and 
increasing the understanding of the underlying mechanisms to their functions in such 
situations would be strongly beneficial.  
 
1.2 - Calcium signalling 
1.2.1 - Calcium signalling – Basic principles and mechanism 
Cellular signalling consists of information transmission, occurring through protein-
protein interactions or via diffusible factors known as second messengers (Berridge, 
2014). Calcium ions (Ca2+) are a type of second messenger, and Ca2+ signalling is key to 
human physiology, required for fertilisation at the beginning of life and cellular 
apoptosis at the end, controlling many cellular processes in between. The basic 
mechanism for calcium signalling comprises a stimulus triggering a transient increase 
in cytoplasmic Ca2+ concentration, known as a calcium ‘response’, or ‘signal’. In order for 
calcium responses to occur, at rest the intracellular Ca2+ concentration is maintained at 
a concentration 20,000-100,000-fold lower than the extracellular Ca2+ concentration 
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(Clapham, 2007). Figure B illustrates and describes the mechanisms behind 
intracellular homeostasis and release.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B – The core of intracellular calcium homeostasis and release. 
The physiological intracellular concentration of calcium is around 100 nM, which is 
maintained by Ca2+ buffers and also by sarcoendoplasmic reticular Ca2+ ATPase (SERCA) and 
plasma membrane Ca2+ ATPase (PMCA) pumps (1), which actively transport Ca2+ into the 
endoplasmic reticulum (ER) and out of the cell through the cell membrane, respectively 
(Clapham, 2007). Some cytosolic Ca2+ is also transported into the mitochondria. 
2. Ca2+ can be released from the ER via inositol 1,4,5-trisphosphate (IP3) and ryanodine (3) 
receptors. IP3 production occurs upon extracellular stimuli-dependent activation of G-protein-
coupled receptors and receptor tyrosine kinases, which then causes release of Ca2+ stored in 
the ER via the IP3 receptor (Berridge, 2014). Ryanodine receptors mediate calcium release 
from the ER following an increase in cytoplasmic Ca2+ concentration, in a calcium-induced 
calcium release manner, subsequently allowing amplification of previous intracellular calcium 
release. Calcium responses can also occur from influx of extracellular Ca2+ through membrane 
ion channels (4), which open upon activation by a stimulus. The schematic diagram was taken 
from Hardin et al., (2012) and annotated. 
 
 
 
1 
2 
3 
4 
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1.2.2 - Calcium signalling – Homeostasis, stores and influx 
A combination of Ca2+-ATPase pumps, Na+/Ca2+ exchangers and Na+/Ca2+-K+ exchangers 
help to maintain the intracellular Ca2+ concentration at around 100 nM. Ca2+-ATPase 
pumps function in an ‘uphill’ manner, with SERCA transferring two Ca2+ ions into the ER 
per ATP molecule hydrolysed, and the PMCA removing one Ca2+ from the cell per ATP 
molecule (Figure B). Conversely, Na+/Ca2+ and Na+/Ca2+-K+ exchangers take advantage 
of inward Na+ currents to send Ca2+ out of the cell. The Na+/Ca2+ exchanger transports 
one Ca2+ ion for every three Na+ ions while the Na+/Ca2+-K+ exchanger co-transports one 
Ca2+ and one K+ for every four Na+ ions (Clapham, 2007).   
Calcium buffer proteins are another key contributor in regulating cytosolic Ca2+ 
concentration, which include the parvalbumins, calbindins and the calretinin protein 
(Schwaller, 2010). Calcium buffers contain evolutionarily conserved structural aspects 
to allow Ca2+-binding to occur with high affinity. Specifically, the EF-hand motif is a 
feature in all the calcium buffer proteins. The resting intracellular Ca2+ concentration is 
typically 20-100 nM, whereas the dissociation constants of calcium buffers is higher, at 
around 0.2-1.5 µM. Owing to this difference, calcium buffers exist in a free state in basal 
conditions, and are thus primed to bind Ca2+ upon cytosolic influx of Ca2+, helping to 
spatiotemporally modulate calcium signals and restore the resting Ca2+ after the signal 
has passed (Schwaller, 2010). Together with the calcium-binding pumps and 
exchangers, calcium buffers maintain an intracellular environment viable for effective, 
but regulated calcium signalling. 
 
As introduced in figure B, there are various means by which calcium influx into the 
cytosol occurs. The phospholipase C pathway is arguably the most common method of 
intracellular calcium release, and occurs initially through activation of cell surface 
receptors such as G protein-coupled receptors. This causes phospholipase C to 
hydrolyse PIP2 into IP3 and DAG, with IP3 triggering calcium release from the ER via the 
IP3 receptor.   
There are several different types of calcium ion channels that allow direct calcium entry 
into the cell (figure B-4), that differ in the type of stimulus that activates them. For 
instance, there are channels that allow influx of calcium upon direct binding of agonists 
such as ATP to the extracellular domains of the respective ion channel, thus also acting 
as a receptor. Additionally, in excitable cells such as neurons and muscle cells, 
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membrane depolarisation causes activation of voltage-gated calcium channels, 
permitting calcium entry. Entry of extracellular calcium can also occur from second 
messengers such as arachidonic acid acting at second messenger-operated channels on 
the cytoplasmic side of the membrane (Berridge, 2014).  
 
Upon activation of the IP3 receptor and calcium release from the ER, the calcium sensor 
STIM1 senses the decrease in ER Ca2+ concentration and activates ORAI1, a Ca2+ release-
activated Ca2+ channel, allowing store-operated Ca2+ entry (Fahrner et al., 2013). The 
purpose of store-operated calcium entry was initially thought to be to replenish 
depleted calcium stores. However, now it has been indicated that the main function may 
be to activate specific signalling pathways by offering Ca2+ to intraceullar recipients 
localised to confined sites close to areas of Ca2+ entry (Putney, 2011). In fact, store-
operated calcium release may be the main signalling pathway for T cell activation and 
mast cell degranulation (Fahrner et al., 2013). 
 
The endoplasmic reticulum is the most characterised intracellular store capable of 
releasing calcium into the cytoplasm, as described in figure B. However, the ER is not 
the only recognised store of calcium ions, as acidic organelles such as lysosomes 
(Churchill et al., 2002), vacuoles (Patel and Docampo, 2010) and acidocalcisomes (Luo 
et al., 2004) have also been shown to store calcium. The calcium-mobilising second 
messenger nicotinic acid adenine dinucleotide phosphate (NAADP) has been suggested 
to cause calcium release from lysosomes (Churchill et al., 2002), although there is little 
evidence for NAADP-induced lysosomal calcium release in leukocytes.  
 
1.2.3 - Calcium signalling - Versatility of Ca2+ signalling and functions 
Calcium responses are temporary but the length of time the transients can persist varies 
widely, which allows many different cellular processes to be mediated through calcium 
signals. For instance, calcium transients responsible for exocytosis last microseconds, 
but responses regulating fertilisation occur for hours (Berridge, 2014). Moreover, 
transient calcium signals can be generated as singular ‘on demand’ pulses upon 
intermittent stimulation, like in neurotransmitter release. Alternatively, they can occur 
as oscillations of brief calcium spikes during continuous cellular stimulation, with the 
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frequency of oscillations dependent on the level of stimulation, as is the case in cell 
proliferation (Berridge, 2014). 
 
In addition to the varied temporal aspects of calcium signalling, there are spatial ones 
too, demonstrating the incredible versatility of calcium signalling. In a similar fashion to 
how calcium signals can occur over a wide time domain, a vast spectrum of locality to 
calcium responses exists. In muscle contraction calcium elevation occurs globally, 
whereas neurotransmitter release is mediated through extremely local, specific delivery 
of Ca2+ to the synaptic vesicle (Berridge, 2014). Regenerating waves of Ca2+ can also 
occur in some cells, such as pancreatic acinar cells, where calcium signals arise in 
precise, fixed points and are propagated along the cytoplasm through the positive 
feedback of calcium-induced calcium release (Dove, 2002).  
 
Once calcium is released into the cytoplasm, various functions can be mediated through 
Ca2+ sensors, which transmit information via Ca2+ effectors. Ca2+ sensors include 
calmodulin, troponin C and DAG kinase α, whereas phosphorylase kinase, calcineurin 
and Ca2+/calmodulin-dependent protein kinases are examples of the many Ca2+ effectors 
(Berridge, 2014). The physiological functions calcium signalling is involved in include 
synaptic transmission, cell proliferation, cellular motility, muscle contraction among 
many more. With particular reference to monocytes, calcium responses have been 
shown to be crucial to their chemotactic (Badolato et al., 1995) and phagocytic 
(Hishikawa, 1991) functions as well as their ability to respond to pro-inflammatory 
molecules such as chemokines (Gouwy et al., 2008). Improving the understanding of 
calcium signalling in monocytes would subsequently be extremely beneficial. 
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1.3 - Purinergic Signalling 
1.3.1 - Purinergic Signalling – Background 
General Concept & Roles in the Human Body 
The incredibly important and rapidly growing field of purinergic signalling revolves 
around the function of purine nucleotides and nucleosides which, aside from their 
obvious critical role in DNA, and as an energy source, also have the capability to act as 
signalling molecules. Purine nucleosides such as adenosine, and nucleotides such as 
ATP and ADP bind to their respective purinergic receptors on the surfaces of cells, and 
cause a downstream cellular change. In the human body, purinergic signalling mediates 
the function of many different processes, in a wide range of organ systems.  
 
For instance, in the immune system, it is well characterised that large increases of 
extracellular ATP acts as a ‘danger signal’, due to ATP release from dying cells 
(Trautmann, 2009). Furthermore, ATP and adenosine are heavily implicated in more 
complex immunomodulation. For example, adenosine reduces peripheral blood 
mononucleated cell (PBMC) release of pro-inflammatory cytokines like TNF-α (Bouma 
et al., 1994), but increases the release of anti-inflammatory mediators such as IL-10 too 
(Le Moine et al., 1996). Moreover, ATP acts as an incredibly potent stimulus in P2X7-
mediated, NALP3-dependent inflammasome activation (Sutterwala et al., 2006). These 
are just a few examples of the ever-growing findings for purinergic signalling in the 
immune system.  
 
Purinergic signalling is also heavily involved in the nervous system, where it is well 
recognised that the purinergic nucleotide ATP is a co-transmitter, or a sole transmitter, 
in most nerves in the central and peripheral nervous systems (Burnstock, 2007). 
Furthermore, among many other neuronal functions, purinergic signalling is involved in 
neuronal-glial and glial-glial communication, which is vital in the processing of 
information in the brain (Fields and Burnstock, 2006).  
In addition to the above, purinergic signalling is also implicated in many other 
physiological systems in the human body, including the digestive, skeletal, and 
respiratory systems. However, purine nucleotides and nucleosides also contribute to 
pathological conditions, such as Alzheimer’s disease (Puertoet al.,2013), cancer (Di 
Virgilio, 2012) and cardiovascular disease (Ralevic and Burnstock, 2003).  
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Early History 
The story behind purinergic signalling first began in 1776, when uric acid, a metabolite 
of purines, was isolated from bladder stones by Carl Wilhelm Scheele (Scheele, 1776). 
However, it was not until the late nineteenth century that several fundamental purines 
themselves, including adenine, were discovered (Jones, 1953). Upon solving the 
structure of caffeine and other associated compounds, Emil Fischer initially coined the 
term ‘purines’ in the early twentieth century (Fischer, 1907). As for purine nucleotides, 
adenosine 5’-triphosphate (ATP) was discovered in 1929 by the independent efforts of 
Cyrus Hartwell Fiske and Yellagaprada SubbaRow in the USA and Karl Lohmann in 
Germany (Fiske and SubbaRow 1929; Lohmann 1929).  
 
Experimental study into the biological effects of purines subsequently ensued, including 
early studies into their effects on the nervous system in the 1940s and 1950s, and 
studies into the more peripheral effects of purines in the 1960s and 1970s (Burnstock 
and Verkhratsky, 2012). A significant moment came in 1978 when Geoffrey Burnstock 
suggested the very first classification of the receptors for purines, with the sub-types 
denoted, as they still are today, as P1 and P2 purinergic receptors (Burnstock, 1978). 
Further details about purinergic receptor sub-classification are described below.  
 
1.3.2 - Purinergic Signalling – Receptor subtypes  
There are two main classes of purinergic receptor, named P1 and P2, with both classes 
also possessing further classification into distinct subtypes. Adenosine is the agonist of 
the P1 receptors, with the four types of P1 receptor present in humans being A1, A2A, 
A2B, and A3. All adenosine receptors are G-protein coupled receptors (GPCRs), with the 
A2A, A2B receptors coupling to Gs proteins, which cause activation of adenylate cyclase 
(AC) and consequently an increase in cytosolic cyclic adenosine monophosphate 
(cAMP). Conversely, A1 and A3 interact with Gi/o proteins, which inhibit AC and cause 
subsequent decrease in cytosolic cAMP concentration (Fredholm et al., 2011). A2B can 
also couple to Gq, inducing IP3 generation and intracellular calcium release (Haskó et al., 
2009). All of the adenosine receptors possess 7 transmembrane domains and all have 
different, although sometimes overlapping, functions. For example, activation of the A1 
receptor inhibits neurotransmitter release from nerve cells, but as with A2A, A1 also 
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plays a role in the heart, with A1 causing a reduction in heart rate, and A2A promoting 
coronary vasodilation (Gao and Jacobson, 2011).  
 
There are two main sub-types of P2 receptors, namely the ionotropic P2X and 
metabotropic P2Y receptors. P2X receptors are ligand-gated ion channels which are 
opened upon binding of ATP (North, 2002). Seven distinct ATP subtypes are known to 
exist in humans, known as P2X1 through P2X7, with all of them able to bind ATP. P2Y 
receptors are G protein-coupled receptors, which bind to, and hence are activated by, a 
variety of nucleotides, depending on the specific P2Y receptor subtype. The P2Y 
receptors that have so far been identified in humans are detailed in the following table. 
 
P2Y Subtype Known ligand(s) G-protein coupling & signal transduction 
P2Y1 ADP Gq – PLCβ, Rac, Rho activation 
P2Y2 ATP, UTP Gq – PLCβ activation 
Go – PLCβ, Rac activation  
G12 – Rho activation 
P2Y4 UTP Gq – PLCβ activation 
Go – PLCβ activation 
P2Y6 UDP, ADP Gq – PLCβ activation 
G12/13 – Rho activation 
P2Y11 ATP Gq – PLCβ activation 
Gs – AC activation 
P2Y12 ADP Gi/o – AC inhibition 
P2Y13 ADP Gi/o – AC inhibition 
P2Y14 UDP-glucose Gi/o – AC inhibition 
Data derived from (Erb and Weisman, 2012). 
 
As with the adenosine P1 receptors, the P2X and P2Y receptors have a multitude of 
functions in health and disease, but the focus here is the ADP receptor P2Y12. 
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1.4 - P2Y12 Receptor 
1.4.1 - P2Y12 Receptor – Background & Function 
In 2001, an elusive ADP receptor in platelets that could inhibit the activity of adenylate 
cyclase was cloned by three independent groups (Hollopeter et al., 2001. Zhang et al., 
2000. Takasaki et al., 2001), and named as P2Y12 by Hollopeter et al., (2001). This 
receptor, which is situated in the plasma membrane lipid rafts and predominantly takes 
the form as a homo-oligomer (Savi et al., 2006), is commonly expressed in platelets, glial 
cells, endothelial cells and smooth muscle cells (Cattaneo, 2006). ADP and its analogues, 
such as 2-methylthio-ADP, cause activation of P2Y12, whereas ATP and its analogues 
inhibit the activity of the receptor (Kauffenstein et al., 2004). Once stimulated, P2Y12 
causes inhibition of adenylate cyclase and subsequent reduction in cAMP levels through 
activation of the Gαi subunit of the G protein that the receptor is coupled to (Quinton et 
al., 2005).  
 
The most established role of P2Y12 is arguably the activation, and aggregation, of 
platelets. Following interaction of platelets with a damaged endothelium, granule 
contents are secreted, which overall comprise over 300 active substances (Golebiewska 
and Poole, 2015). There are different types of intracellular granule, such as alpha and 
dense, each comprising different contents (Golebiewska and Poole, 2015). The released 
contents of dense granules include ADP, which elicits its effect though the P2Y1 and 
P2Y12 receptors on platelets, with P2Y12 forming a crucial role in platelet function. For 
example, P2Y12 has been found to potentiate dense granule secretion (Dangelmaier et 
al., 2001), activate the fibrinogen receptor (Jin and Kunapuli, 1998), and cause 
thrombus formation (van Gestel, 2003). Furthermore, although P2Y12 has not been 
found to play a direct role in ADP-evoked platelet morphology change or intracellular 
calcium release, the Gi signalling activated by P2Y12 can ultimately induce platelet 
aggregation upon simultaneous Gq/G12/13 pathway activation (Jin and Kunapuli, 1998), 
or by itself with high ADP concentrations (Ohlmann et al., 2000). The P2Y12 signalling 
pathway also potentiates procoagulant activity (Kunapuli et al., 2003), α-granule release 
(Zhao et al., 2001), and P-selectin expression (Storey et al., 2002) in platelets. To 
summarise, P2Y12 activation plays a vital role in haemostasis by stimulating granule 
secretion, platelet aggregation, procoagulant activity, and recruitment of platelets to 
injury sites. 
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1.4.2 - P2Y12 Receptor – Roles in human disease  
P2Y12 has a vital role in haemostasis, as previously described, with those having a defect 
in P2Y12 suffering bleeding diathesis, as characterised by excessive post-surgical and 
post-traumatic blood loss (Cattaneo, 2010). However, along with its haemostatic role in 
health, P2Y12 is implicated in thrombus formation in atherosclerosis. Upon rupture of a 
vulnerable plaque, lipids, collagen and smooth muscle cells are exposed, causing 
activation of platelets and the coagulation cascade, resulting in the formation of a 
potentially occluding thrombus (Bentzon et al., 2014). Attempting to avoid the 
formation of a potentially life-threatening coronary thrombus using antiplatelet 
therapies is therefore of great use. Research from as early as the 1980s, even before 
P2Y12 was cloned, showed that inhibition of P2Y12 significantly reduced the risk of 
vascular thrombotic events (Cattaneo, 2015). One of the initial P2Y12-targeted 
thienopyridine antiplatelet drugs, ticlopidine, proved effective in inhibiting platelet 
function and reducing vascular thrombotic events (Cattaneo, 2010). Ticlopidine is 
rarely used now, however, due to its toxicity. Other new generation anti-P2Y12 drugs 
such as ticagrelor and prasugrel are now commonly used antiplatelet therapies that 
have proved more effective in preventing major cardiovascular events in those with 
acute coronary syndromes, with ticagrelor in particular being associated with a 
significant reduction in mortality (Cattaneo, 2015).  
      
The role for platelet P2Y12 in atherothrombosis is clear, however this receptor has 
potential atherosclerotic functions in other cells. Notably, findings by West et al. (2014) 
suggest a role for vessel wall, rather than platelet, P2Y12 in early atherogenesis. 
Compared to the ApoE-knockout control, ApoE-deficient mice lacking in vessel wall 
P2Y12 exhibited significantly reduced atheroma, which was conversely not the case in 
ApoE-knockout mice deficient in platelet P2Y12. Although, this study did not state which 
specific cell types in the vessel wall express P2Y12. Furthermore, mice given doses of 
ticagrelor or clopidogrel lasting four weeks did not show any significant reduction in 
atheroma formation compared to the control. This study used bone marrow transplants 
generating chimeric mice in an attempt to establish the role of platelet or vessel wall 
P2Y12. However, the study did not investigate the effect of P2Y12 deficiency in other 
bone-marrow derived cells, such as monocytes. Therefore, although an atherogenic role 
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for P2Y12 outside platelets has been suggested, these findings are limited, and so 
investigating the expression and function of P2Y12 in human monocytes would be very 
useful. In addition to cardiovascular disease, P2Y12 has potentially been implicated in 
immune responses to ADP in macrophages (Zhang et al., 2016) and dendritic cells (Ben 
Addi et al., 2010) in functions such as antigen uptake and chemotaxis. Therefore, non-
platelet roles for P2Y12 have been suggested and should be further investigated. This 
project aims to establish the expression of P2Y12 in monocytes and to gain insight into 
the role of the receptor in ADP-evoked calcium responses in THP-1 cells.  
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Chapter 2 – Materials & Methods 
2.1 - Chemicals, reagents and dilutions 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma-Aldrich, 
with the exception of Pertussis Toxin and SQ22536 (Tocris). All chemicals (agonists and 
antagonists) were diluted using SBS buffer (containing (mM): NaCl, 130; KCl, 5; MgCl2, 
1.2; CaCl2, 1.5; D-glucose, 8; HEPES, 10; pH 7.4) with the exception of CCL2 (SBS buffer 
containing 1% bovine serum albumin), MRS2578, LY294002, SQ22536 and ticagrelor 
(SBS buffer containing 1% DMSO). 
 
2.2 – THP-1 Cell culture & CD14+ cells 
Cells from the THP-1 cell line, which is a human monocytic cell line cultured from the 
blood of an acute monocytic leukaemia patient (Tsuchiya et al., 1980), were cultured at 
37°C and 5% CO2 in RPMI 1640 medium containing 2 mM L-glutamine (ThermoFisher) 
and supplemented with 10% (v/v) foetal bovine serum (FBS), 50 IU/ml penicillin and 
50 µg/ml streptomycin (ThermoFisher). Cells were maintained at a density between 1 x 
105 and 1 x 106 cells/ml.  
CD14+ monocyte RNA was kindly donated by Dr. Priscilla Day, a colleague, who 
extracted the RNA from CD14+ cells obtained from PBMCs isolated from the blood of 
human volunteers.  
 
2.3 - Measurement of intracellular calcium 
1 x 106 THP-1 cells/ml were loaded with 2 μM Fura-2 in SBS buffer plus 0.01% (w/v) 
pluronic acid to ensure that fura-2 is internalised into the cell and can therefore 
sufficiently bind to intracellular Ca2+. The loading time was 1 hour at 37°C with gentle 
shaking of the cells every 15 minutes. After loading, the cells were pelleted and washed 
with 20 ml excess SBS buffer before being plated in a clear-bottomed 96-well plate at a 
density of 2x105 cells/well. The plated cells were allowed to settle for 1 hour at 37°C, 
during which stage antagonists were added 30 minutes into the hour, unless otherwise 
stated. The FlexStation® 3 instrument (Molecular Devices) adds a 50 μl volume of 
prepared agonist to the cells and subsequently measures fura-2 fluorescence (340 nm 
excitation when Ca2+-bound; 380 nm excitation when unbound; 510 nm emission) at 
intervals of 4 seconds at 37°C giving representative traces of F ratio (ratio between 340-
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380nm excitation) vs. time. The operation of the FlexStation instrument was managed via 
Softmax Pro software, which also allowed raw data to be collected. SoftMax Pro 
subtracted the detected resting Ca2+ level prior to challenging with agonists, giving 
representative traces of F ratio vs. time starting at 0.  
 
2.4 - Immunocytochemistry 
Cover slips were inserted into 6-well clear-bottomed plates and were coated with 
polylysine overnight to improve adherence of the THP-1 cells which were then seeded on 
the slides and incubated for 2 hours. The cells were then washed twice with phosphate-
buffered saline (PBS), fixed with 4% (w/v) paraformaldehyde in PBS (pH 7.4), washed 
twice with PBS and then permeabilised by incubating with 0.25 % (v/v) Triton X-100 
(ThermoFisher) in PBS for 10 minutes. After washing with PBS three times for 5 minutes, 
the cells were blocked by incubating them with 1% (w/v) BSA in PBS for 30 minutes at 
room temperature. The primary antibody (Goat polyclonal IgG, Santa Cruz Biotechnology 
no. # sc-27152) was diluted to an antibody/cells ratio of 1/200 in 1% (w/v) BSA and 
added to the cells which were then incubated overnight at 4 °C. The secondary antibody 
(Rabbit anti-Goat polyclonal IgG conjugated to Alexa Fluor® 488, Abcam no. #ab150141) 
was diluted to an antibody/cells ratio of 1/1000 in 1% (w/v) BSA and added to the cells 
which were then incubated in the dark for 60 minutes at room temperature. 
VECTASHIELD®, containing DAPI (Vector Laboratories), was added to microscope slides 
and, after washing with PBS three times for 5 minutes, the cover slips, containing the cells, 
were placed cells-side down onto the VECTASHIELD®. The edges of the cover slip were 
sealed with nail polish to ensure an air-tight environment for the cells, and the 
microscope slides were kept at 4 ºC in the dark.  
 
2.5 - RNA extraction 
1 x 106 cells were centrifuged at 2000 rpm for 7 minutes, and the supernatant was 
removed. The pellet was lysed with 1 ml Tri reagent and vortexed until no cellular 
debris was present. The cell lysate was allowed to stand for 5 minutes at room 
temperature before 0.1 ml 1-bromo-3-chloropropane was added to the lysate, which 
was then vortexed and allowed to stand for 15 minutes at room temperature. The 
mixture was then centrifuged at 14,800 x g for 15 minutes at 4 °C, which caused 
separation of the resulting suspension into three phases, with the top aqueous phase 
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contains the RNA. The aqueous phase was transferred to a new 1.5 ml Eppendorf tube, 
along with 0.5 ml 2-propanol, and the mixture was vortexed for 15 seconds. The 
mixture was allowed to stand at room temperature for 10 minutes before being 
centrifuged at 14,800 x g for 10 minutes at 4 °C. The resulting pellet contains the RNA, 
therefore the supernatant was carefully removed, and the pellet was vortexed for 15 
seconds with 1 ml 75% pre-chilled ethanol to wash the pellet. The mixture was 
centrifuged at 14,800 x g for 10 minutes and the supernatant was removed before 
allowing the pellet to be air-dried for 15 minutes in a sterile hood. A 40 µl amount of 
RNase-free water was added, and the mixture gently resuspended before heating for 5 
minutes at 65 ºC. The resulting RNA quality and quantity was determined using a 
Nanodrop spectrophotometer.  
 
2.6 - Reverse-Transcription Polymerase Chain Reaction  
2.6.1 - Reverse transcription 
RNA was primed by adding 200 ng of random hexamers (Invitrogen) to 1 µg RNA, with 
RNase-free water added to make the solution up to a total volume of 11 µl, which was 
then incubated for 10 minutes at 70 ºC. A master-mix was made, containing 4 µl 5x first 
strand buffer (Invitrogen), 2 µl 0.1M DTT (Invitrogen), 1 µl Superscript II reverse 
transcriptase (200U) (Invitrogen) (substituted with 1 µl RNase-free water for no-RT 
control), 0.5 µl dNTPs (10 µM) (Promega), 0.75 µl RNasin® ribonuclease inhibitor 
(30U) (Promega) and 0.75 µl RNase-free water, which was added to the randomly 
primed RNA and incubated for 1 hour at 42 ºC and then for 10 minutes at 70 ºC. The 
resulting cDNA was then stored at -20 ºC. 
 
2.6.2 - Polymerase chain reaction 
PCR was performed according to the procedure listed in the Sigma-Aldrich ‘ReadyMix™ 
Taq PCR Reaction Mix with MgCl2’ product technical bulletin, which was implemented 
using the conditions outlined below. Separate template-positive and non-template tubes 
were prepared for each PCR reaction.  Each template-positive PCR tube consisted of 12.5 
µl ReadyMix™ Taq PCR Reagent Mix, 0.5 µl forward primer, 0.5 µl reverse primer, 2 µl 
template cDNA and the total volume was made up to 25 µl using PCR water. Each non-
template tube contained the same amounts of reagents as above, with the exception of 2 
µl template cDNA, which was substituted with 2 µl PCR water. The tubes for each reaction 
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were flicked to ensure mixing, and centrifuged briefly to allow sedimentation before 
being inserted into an ‘Eppendorf Mastercycler EP S’ thermal cycler. The samples were 
heated to 94 ºC for 4 minutes to enable activation of the enzymes included in the 
ReadyMix™ Taq PCR Reagent Mix. The samples were then subjected to 35 cycles of the 
following thermal cycling conditions; the cDNA templates were denatured at 94 ºC for 1 
minute, annealing of primers at 55 ºC for 2 minutes, and extension of product at 72 ºC for 
3 minutes. The PCR products were then kept in the cycler at 4 ºC until they could be 
removed 1-2 hours later.  
 
Primer details 
Gene Accession no. Sequence Size (bp) 
P2RY1 NM_002563 
GTTCAATTTGGCTCTGGCCG (5’-3’) 
TTTTGTTTTTGCGGACCCCG (3’-5’) 
326 
P2RY6 NM_176798 
GCTCTCACTGTCATCGGCTT (5’-3’) 
TCTGCCATTTGGCTGTGAGT (3’-5’) 
391 
P2RY12 NM_022788 
ACTGGGAACAGGACCACTGA (5’-3’) 
CAGAATTGGGGCACTTCAGC (3’-5’) 
698 
P2RY13 NM_176894 
TTCCCAGCCCTCTACACAGT (5’-3’) 
GGCCCCTTTAAGGAAGCACA (3’-5’) 
461 
 
2.7 - Quantitative Real-time Polymerase Chain Reaction 
The following was added into each well of a 96-well qPCR plate; 10 µl TaqMan® Gene 
Expression Master Mix (ThermoFisher), 1 µl Applied Biosystems® Custom TaqMan® 
MGB Probes (P2Y12, GAPDH, B2M) and 4 µl molecular grade water. Followed by 5 µl of 2 
ng/µl cDNA into each well. The plate was then sealed and centrifuged at 1000 rpm for 1 
minute before being subjected to the default run method included in the Applied 
Biosystems® 7500 Fast Real-Time PCR System, in which the plate was analysed. Relative 
quantifications of mRNA were calculated using the ∆∆CT method. The geomean of GAPDH 
and B2M expression was used for a housekeeping control.  
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2.8 - Agarose Gel Electrophoresis 
A 2% (w/v) Agarose gel was made using Agarose powder and 1 X TAE buffer, with 3 µl 
ethidium bromide added. A 5 µl amount of loading dye was added to the samples intended 
to be run and also to the DNA ladder. The DNA ladder and the samples were added to the 
wells (30 µl) and electrophoresis was performed at 90V. 
 
2.9 - Human P2Y6-overexpressing 1321N1 cells 
Astrocytomas from the 1321N1 cell line overexpressing human P2Y6 were donated as a 
gift from Jean-Marie Boeynaems (The Université libre de Bruxelles). The transfection, as 
conducted by Jean-Marie Boeynaems, was achieved using a recombinant pcDNA3 
plasmid encoding human P2Y6, as described in Communi et al. (1996). The cells were 
cultured under G418 selection (0.4 mg/ml) at 37°C and 5% CO2 in DMEM medium 
supplemented with 10% (v/v) FBS, 50 IU/ml penicillin and 50 µg/ml streptomycin. For 
calcium experiments 2.5 x 104 cells/well were plated overnight in clear-bottomed black 
96-well plates and measured for intracellular calcium the next day using the method 
described previously. 
 
2.10 - P2Y12-knockdown THP-1 cells 
THP-1 cells were incubated overnight in complete RPMI (+ 10% FBS) without antibiotic 
before cells were transfected using siRNA and DharmaFECT 2 transfection reagent 
(Dharmacon Research) using the following protocol in 96-well format. Two tubes 
denoted as tube 1 and tube 2 were prepared using the following method (quantities are 
per well); tube 1 - 0.5 µl of 5 µM siRNA was gently mixed with 9.5 µl Optimem 
(ThermoFisher), tube 2 - 0.5 µl of DharmaFECT 2 was gently mixed with 9.5 µl 
Optimem. Tubes 1 & 2 were incubated for 5 mins at room temperature before adding 
the contents of tube 1 to tube 2 to form a transfection medium, and then incubating at 
room temperature for a further 20 mins. THP-1 cells were then counted, centrifuged 
and the resulting pellet resuspended with complete RPMI. Cells were prepared for a 
final amount of 1x105 cells/well, with a volume of 80 µl of the cell suspension added to 
the aforementioned transfection medium. The cells, combined with the transfection 
medium, were then plated in a 96-well plate and incubated at 37°C, 5% CO2 for 48 hrs 
before proceeding with specified experiments.  
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Three different siRNA treatments were prepared per experiment; P2Y12-targeted 
(ThermoFisher #AM16708), GAPDH-targeted (ThermoFisher #AM4605), or negative 
control siRNA (Ambion® Silencer® Negative Control #1 - ThermoFisher #AM4611), 
and the final siRNA concentration in each experiment was 25 nM. 
 
2.11 - Statistical analysis 
Data analysis was performed using Origin Pro 9.0 software (Origin Lab, USA). Dose–
response curves were fitted by Origin, which used the Hill equation below to determine 
the degree of ligand-receptor cooperation. Figure data points represent mean values ± 
standard error of the mean (error bars). Statistical significance was determined using 
paired Student t-tests. Each point in the dose-response plots represents the mean of the 
peaks from the respective Flexstation f-ratio outputs. 
As obtained from Origin software, the following shows the equation of the Hill curve used 
when plotting dose-response curves, where k represents the Michaelis constant and n 
represents the Hill coefficient: 
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2.12 - Pharmacological inhibitors used 
Name Function Reported IC50 IC50 
Reference 
U73122 PLC inhibitor 1.5-1.8 µM 
(rodent osteoblastic cells)  
Tatrai et al., 
1994 
Thapsigargin SERCA 
inhibitor 
30 nM 
(rat liver microsomes) 
Thastrup et 
al., 1990 
Ticagrelor P2Y12 
antagonist 
0.24 µM 
(platelet aggregation) 
FDA, 2009 
PSB-0739 Selective P2Y12 
antagonist 
Ki – 25 nM (Baqi et al., 
2009) 
MRS 2578 Selective P2Y6 
antagonist 
37 nM ± 16 
(1321N1 astrocytomas) 
Mamedova 
et al., 2004 
MRS 2500 Selective P2Y1 
antagonist 
0.95 nM  
(platelet aggregation) 
Cattaneo et 
al., 2004 
MRS 2211 Selective P2Y13 
antagonist 
pIC50 – 5.97  
(1321N1 astrocytomas) 
Kim et al., 
2005 
NBMPR ENT-1 inhibitor 3.6 nM ± 1.4  
(Xenopus oocytes) 
Yao et al., 
1997 
LY294002 PI3K inhibitor 1.4 µM Viahos et 
al., 1994 
Pertussis Toxin Inhibits 
coupling to Gi 
protein 
~16 ng/ml (2hr 
incubation) 
(Rat adenohypophyseal 
cells) 
Musset et 
al., 1990 
SQ22536 Adenylate 
cyclase 
inhibitor 
21 µM 
(Human blood platelets) 
Harris et al., 
1979 
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Chapter 3 – Results 
 
3.1 - Establishing ADP-evoked calcium responses in THP-1 monocytes 
3.1.1 - Introduction & Aim 
Calcium responses in human cells can occur through different methods. The mechanism 
investigated is the phospholipase C pathway, which is described as follows. A certain 
type of cell surface receptor, called G protein-coupled receptors, are activated by 
external stimuli, such as extracellular nucleotides, causing activation of PLC. PIP2 is 
then hydrolysed by PLC into IP3 and DAG. IP3 subsequently causes release of calcium 
ions from the endoplasmic reticulum through IP3 receptors, giving rise to a sharp 
increase in cytosolic calcium ion concentration.  
 
Before investigating the function of P2Y12 in monocytes, it would be useful to establish 
ADP-evoked calcium responses, and attempt to confirm whether ADP causes calcium 
responses via the classical signalling transduction pathway described above. In order to 
do this, calcium responses were measured in THP-1 cells when stimulated with ADP. 
Moreover, the effect of selective inhibitors for some proteins involved in the signalling 
pathway described above on ADP-evoked calcium responses was also determined.  
The half-maximal effective concentration (EC50) for ADP-evoked maximal platelet 
aggregation in Ossabaw swines was reported as being 3.64 μM ± 2.2 μM (Kreutz et al., 
2011), thus influencing the choice of ADP concentrations used in figure 1.  
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3.1.2 Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The findings shown in figure 1 suggest that ADP does induce calcium responses in THP-
1 cells, with an observed EC50 of 2.66 µM ± 0.25. 
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Figure 1 – ADP evokes calcium responses in THP-1 cells in a dose-
dependent manner 
Fura-2-loaded THP-1 monocytes were challenged with either 3 µM ADP 
(A), or increasing concentrations of ADP (B). Shown is a representative 
time-resolved trace (A), and a dose response curve of the peaks of the 
calcium responses (B), represented in the form of F Ratio (340/380), with 
the data points representing mean ± SEM. ADP EC50 = 2.66 µM ± 0.25. N=3 
A 
B 
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Figure 2 – The Phospholipase C inhibitor U73122 abolishes ADP-
evoked calcium responses in THP-1 monocytes 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 5 µM 
U73122 or a vehicle control before being challenged with 30 or 3 µM ADP. 
Shown are the representative traces of the calcium responses, represented 
in the form of F Ratio (340/380), with the data points representing mean ± 
SEM. N=3.  
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To test whether calcium responses evoked by ADP are mediated through activation of 
PLC, the effect of a selective PLC inhibitor U73122 (5 µM) on ADP-evoked calcium 
responses was determined in THP-1 cells, with the results shown in figure 2. U73122 
totally abolished calcium responses induced by maximal (30 µM), and approximate 
EC50 (3 µM) ADP concentrations, indicating that ADP-induced calcium responses are 
dependent on PLC activation. As Gq-coupled receptor activation causes PLC stimulation, 
this indicates that the calcium responses evoked by ADP are primarily mediated 
through a Gq-coupled receptor.  
 
Another study showed that U73122 inhibited endothelin-1- and parathyroid hormone-
evoked intracellular calcium signals in rodent osteoblastic cells with an IC50 of 1.5-1.8 
µM (Tatrai et al., 1994).  
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Figure 3 – The SERCA inhibitor thapsigargin abolishes ADP-evoked 
calcium responses in THP-1 monocytes 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 1 µM 
thapsigargin or a vehicle control before being challenged with 30 µM ADP. 
Shown are the representative traces of the calcium responses, represented 
in the form of F Ratio (340/380), with the data points representing mean ± 
SEM. N=3.  
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Classical Gq protein-coupled receptor-mediated calcium responses occur through 
calcium release from the endoplasmic reticulum (ER), and the sarco-endoplasmic 
reticulum. The Ca2+-ATPase (SERCA) calcium ion pump is responsible for transferring 
calcium ions into the ER and therefore maintaining the calcium store. Inhibition of 
SERCA would deplete the ER calcium store, and the effect of the SERCA inhibitor 
thapsigargin on ADP-evoked calcium responses was investigated in THP-1 cells. 
 
Figure 3 shows that thapsigargin eliminates calcium responses evoked by a maximal 
concentration of ADP, indicating that ADP-induced calcium responses are dependent 
upon the ER store of calcium ions. In summary, the results from figures 2 and 3 suggest 
that calcium responses evoked by ADP in THP-1 cells are mediated by the signal 
transduction pathway downstream of Gq protein-coupled receptor activation, which 
was the expected outcome. A previous study demonstrated that thapsigargin inhibits 
the Ca2+-ATPase activity of rat liver microsomes with an IC50 value of 30 nM (Thastrup 
et al., 1990), supporting the choice of thapsigargin concentration in figure 3 as a 
maximal concentration. Furthermore, thapsigargin-mediated inhibition of the 
endoplasmic reticulum isoform of the Ca2+-ATPase in rat liver microsomes was shown 
to be selective, as thapsigargin had little effect on plasma membrane Ca2+-ATPases in 
hepatocytes or erythrocytes, or on the sarcoplasmic reticulum of cardiac or skeletal 
muscle cells (Thastrup et al., 1990). 
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3.2 - Characterising the expression of P2Y12 in human monocytes 
3.2.1 - Introduction & Aim 
It has been shown in previous studies that the P2Y12 receptor is expressed in platelets, 
microglia, endothelium and smooth muscle cells (Cattaneo, 2006), however there are no 
publications to date that have characterised the expression of P2Y12 in monocytes. In 
order to investigate the involvement of P2Y12 in ADP-evoked calcium responses in 
monocytes, it was necessary to confirm the gene and protein expression of P2Y12 in 
these cells. P2Y12 gene expression in both THP-1 cell line monocytes and CD14+ primary 
monocytes was determined to ensure that P2Y12 expression is not a cell-line specific 
artefact. The aim here was also to establish the gene expression of other P2Y receptors 
activated by ADP to highlight the other possible candidate receptors involved in 
mediating the ADP-evoked calcium response in monocytes. This was a useful step which 
helped to assess what ADP-activated P2Y receptors are present in monocytes before 
pharmacologically investigating the specific potential receptors involved in mediating 
ADP-induced calcium responses. RT-PCR was used to determine gene expression, with 
immunocytochemistry used to establish the protein expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 39 
 
3.2.2 - Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results in figure 4 show that the ADP-responsive P2Y receptors P2Y1, P2Y6, P2Y12 
and P2Y13 are expressed at the mRNA level in THP-1 cells. Therefore, all such receptors 
were considered when proceeding with investigating the P2Y receptors responsible for 
ADP-evoked calcium responses in THP-1 cells. P2Y12 mRNA was shown also to be 
expressed in primary CD14+ monocytes to indicate that P2Y12 epression in THP-1 
monocytes is not a cell-line specific artefact.  
  
 
 
 
 
 
 
 
Figure 4 – The P2Y12 gene is expressed at the mRNA level in THP-1 and CD14+ 
monocytes   
PCR was conducted as stated in materials and methods using cDNA from THP-1 (A) 
and primary CD14+ (B) monocytes, with the products separated using agarose gel 
electrophoresis. Expected band sizes for ADP P2Y receptors (bp) - P2Y1:  326, P2Y6:  
391, P2Y12: 698, P2Y13: 461. ‘no RT’ indicates negative control products from PCR 
reactions in the absence of reverse transcriptase. N=1. 
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Figure 5 – P2Y12 protein is expressed in THP-1 cells 
Immunocytochemistry was performed as stated in materials and methods to generate 
THP-1 monocytes stained for P2Y12 (intracellular epitope) using a fluorescent-green 
AF488-conjugated secondary antibody. The images taken from confocal microscopy 
above show (A) cells with both primary and secondary antibodies present and (B) the 
negative control with only the secondary antibody present. Cells were counter-stained 
with DAPI (blue). The two images have been equally exposed. N=1. 
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An antibody directed against an intracellular P2Y12 epitope was used during the 
immunofluorescent staining of P2Y12, and the confocal images of the cells show in 
figure 5 that P2Y12 protein is expressed in THP-1 monocytes. This correlates with the 
results from figure 4 to confirm that THP-1 P2Y12 mRNA is translated into protein in the 
cell.
3.3 - Pharmacological dissection of ADP-activated P2Y receptors in THP-1 cells 
3.3.1 - Introduction & Aim 
The G protein-coupled P2Y receptors P2Y1, P2Y6, P2Y12 and P2Y13 all have the capability 
to be activated by ADP and may theoretically contribute to the ADP-induced calcium 
response. Calcium responses triggered through the phospholipase C pathway can occur 
upon the activation of Gq-coupled receptors, which causes PLC-mediated breakdown of 
PIP2 into IP3 and DAG and subsequent calcium ion (Ca2+) release through endoplasmic 
reticulum IP3 receptors. P2Y1 and P2Y6 are Gq-coupled and therefore can evoke such 
calcium responses when activated by ADP. P2Y12 is Gi coupled, and Gi-coupled P2Y 
receptors have not been shown to directly cause cytosolic Ca2+ release, but cause 
inhibition of adenylate cyclase instead. Therefore, it may seem unlikely that P2Y12 
would contribute to ADP-evoked calcium responses. However, there have been 
numerous studies in platelets demonstrating that P2Y12 modulates the calcium response 
mediated by P2Y1 activation, indicating that it would be worthwhile to investigate 
whether P2Y12 is involved in ADP-evoked calcium responses in THP-1 cells. 
 
The objective here was to determine the effect of using pharmacological inhibitors for 
P2Y1, P2Y6, P2Y12 or P2Y13 to indicate which of these ADP receptors have an 
involvement in causing calcium responses to ADP in THP-1 cells. The focus here was on 
the involvement of P2Y12, however it was important that all aforementioned ADP-
activated P2Y receptors were considered, particularly as they were all found to be 
expressed in THP-1 monocytes.  
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3.3.2 - Results 
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Figure 6 – Ticagrelor attenuates ADP-evoked calcium responses in a 
dose-dependent manner 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 3 
µM ticagrelor (A), or increasing concentrations of ticagrelor (B) before 
being challenged with 3 µM ADP. Shown are representative time-resolved 
traces (A), and an inhibitory dose response curve of the peaks of the 
calcium responses (B), represented in the form of F Ratio (340/380), with 
the data points representing mean ± SEM. Ticagrelor IC50 = 1.29 µM 
(calculated manually due to plotting issues with Origin). N=3. * denotes 
P<0.005 vs ‘3 µM ADP + vehicle control’ 
A 
B 
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Ticagrelor is a clinically-administered P2Y12 antagonist, and Figure 6 illustrates the 
effect of using ticagrelor to inhibit the calcium responses induced by an approximate 
EC50 ADP concentration of 3 µM in THP-1 cells. There is a clear concentration-
dependent effect of ticagrelor on ADP-evoked calcium responses indicated by the 
inhibitory dose-response curve generated.  
 
The FDA reported in 2009 that ticagrelor inhibited 6.5 µM ADP-induced platelet 
aggregation in human blood in a dose dependent manner, yielding a half-maximal 
inhibitory concentration (IC50) of 0.24 µM. This helped determine the concentration 
range of ticagrelor to use for figure 6. 
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Figure 7 – Ticagrelor inhibits ADP-evoked calcium responses in a 
non-competitive manner 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 0.1, 
1 or 5 µM ticagrelor or vehicle control before being challenged with 30 µM 
(A), or increasing concentrations of ADP (B). Shown are representative 
time-resolved traces (A) and the dose response curves of the peaks of the 
calcium responses (B), represented in the form of F Ratio (340/380), with 
the data points representing mean ± SEM. ‘ADP + vehicle control’ Emax = 0.7, 
‘ADP + 0.1 µM ticagrelor’ Emax = 0.58, ‘ADP + 1 µM ticagrelor’ Emax = 0.33, 
‘ADP + 5 µM ticagrelor’ Emax = 0.30. The data was normalised to the highest 
value generated from all repeats across the treatments. N=3. * denotes 
P<0.05 vs ‘ADP + vehicle control’ of Emax value, and between peaks in (A), as 
determined by a paired student’s t-test. 
A 
B 
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The effect of 3 increasing Ticagrelor concentrations on calcium responses induced by 
ADP is illustrated in figure 7. Ticagrelor concentrations of 1 and 5 µM caused a 
significant reduction in the maximal effect of the agonist (Emax), with 5 µM ticagrelor 
representing an approximate IC50 concentration. This reduction in Emax demonstrates 
that ticagrelor acts as a non-competitive inhibitor for ADP-evoked calcium responses in 
THP-1 cells. This is consistent with the findings observed by van Giezen et al. (2009), 
who report that ticagrelor binds to P2Y12 independently from ADP, and non-
competitively inhibits ADP-induced aggregation of human washed platelets. 
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Figure 8 – PSB-0739 reduces ADP-evoked calcium responses in a dose-
dependent manner in THP-1 cells 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 25 µM 
PSB-0739 (A) or increasing concentrations of PSB-0739 (B) before being 
challenged with 3 µM ADP. Shown are representative time-resolved traces (A) 
and an inhibitory dose response curve of the peaks of the calcium responses 
(B), represented in the form of F Ratio (340/380), with the data points 
representing mean ± SEM. PSB-0739 IC50 = 5.61 µM ± 2.1. N=3. * denotes 
P<0.05 and ** denotes P<0.01 vs ‘3 µM ADP + vehicle control’. 
A 
B 
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To determine whether P2Y12 inhibitors other than ticagrelor could have similar effects 
to the findings presented in figures 6 and 7, the impact of PSB-0739, an alternative 
selective P2Y12 antagonist, on 3 µM ADP-evoked calcium responses was assessed, the 
data are presented in figure 8. As seen from the evident inhibitory dose-response curve 
shown, PSB-0739 caused a concentration-dependent effect on ADP-induced calcium 
responses in THP-1 cells. PSB-0739 was found here to have an IC50 of 5.6 µM ± 2.1 for 
ADP-evoked calcium responses, which is a similar IC50 to that observed for ticagrelor 
from figure 4. There are no relevant published IC50 values to compare to, however PSB-
0739 has a reported Ki of 25 nM (Baqi et al., 2009), which would suggest it is highly 
potent, however Ki, which measures inhibitor-receptor affinity, does not always 
correlate with efficacy.  
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Figure 9 – PSB-0739 inhibits ADP-evoked calcium responses in a 
competitive manner in THP-1 cells 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 5 or 10 
µM PSB-0739 or a vehicle control before being challenged with 3 µM (A) ADP 
or increasing concentrations of ADP (B). Shown are the representative time-
resolved traces (A) and the dose response curves of the peaks of the calcium 
responses (B), represented in the form of F Ratio (340/380), with the data 
points representing mean ± SEM. ‘ADP + vehicle control’ EC50 = 2.68 µM ± 0.26, 
‘ADP + 5 µM PSB-0739’ EC50 = 6.36 µM ± 0.74, ‘ADP + 10 µM PSB-0739’ EC50 = 
7.93 µM ± 1.47. The data was normalised to the highest value generated from 
all repeats across the treatments. N=3. EC50 values in (B) between effect of 10 
µM PSB-0739 vs. vehicle control are significantly different to P<0.05. 
A 
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Figure 9 shows the effect of pre-incubating two different PSB-0739 concentrations on 
subsequent calcium responses induced by ADP. PSB-0739 caused a dose-dependent 
rightward shift in the ADP-evoked dose-response curve, and a dose-dependent increase 
in EC50 value, indicating that PSB-0739 acts competitively in inhibiting ADP-evoked 
calcium responses. Furthermore, 10 µM caused a statistically significant increase in 
EC50. It is well established in literature that PSB-0739 acts as a competitive antagonist, 
as found by Hoffmann et al. (2009) for example, who found that PSB-0739 caused a 
rightward shift in the inhibitory dose-response curve caused by 2-methylthio-ADP-
induced reduction of forskolin-evoked cAMP production in Chinese hamster ovary cells. 
 
Overall the results shown in figures 6-9 suggest that ADP-evoked calcium responses in 
THP-1 cells are dependent on P2Y12 activation due to the fact that the P2Y12 inhibitors 
Ticagrelor and PSB-0739 cause significant decrease in ADP-evoked calcium responses.  
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Figure 10 – The P2Y6 inhibitor MRS 2578 reduces ADP-evoked 
calcium responses in a dose-dependent manner 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with a 
vehicle control or 10 µM MRS 2578 (A), or increasing concentrations of 
MRS 2578 (B), before being challenged with 3 µM ADP. Shown are 
representative time-resolved traces (A) and an inhibitory dose response 
curve of the peaks of the calcium responses (B), represented in the form of 
F Ratio (340/380), with the data points representing mean ± SEM. MRS 
2578 IC50 = 0.2 µM ± 0.029. * denotes P<0.05 and ** denotes P<0.01 vs ‘3 
µM ADP + vehicle control’. 
A 
B 
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P2Y6 is primarily a UDP receptor but it can also be activated by its partial agonist ADP 
(Communi et al., 1996), and with the purpose of determining the role that ADP 
receptors other than P2Y12 play in ADP-induced calcium responses, the effect of a P2Y6 
inhibitor on ADP-evoked calcium responses was established. In a similar fashion to the 
P2Y12 inhibitors, the P2Y6 inhibitor MRS 2578 caused a dose-dependent reduction in 
calcium responses evoked by an approximate EC50 concentration of ADP, as 
demonstrated in figure 10.  
 
MRS 2578 has been reported elsewhere to have a concentration-dependent inhibitory 
effect on phospholipase C (PLC) activity induced by P2Y6 activation with an IC50 of 37 
nM ± 16 in human P2Y6-transfected 1321N1 human astrocytomas (Mamedova et al., 
2004). This served as a useful guide in determining the concentration range of MRS 
2578 to be used here.  
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Figure 11 – MRS 2578 inhibits ADP-evoked calcium responses in a non-
competitive manner 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 0.3 µM 
MRS 2578 or a vehicle control before being challenged with 10 µM ADP (A) or 
increasing concentrations of ADP (B). Shown are representative time-resolved 
traces (A), and dose-response curves of the peaks of the calcium responses (B), 
represented in the form of F Ratio (340/380), with the data points representing 
mean ± SEM. ADP + ‘vehicle control’ Emax = 2.12, ‘ADP + 0.3 µM MRS 2578’ Emax = 
1.36. N=3. Emax values in (B) between effect of 0.3 µM MRS 2578 vs. vehicle 
control are significantly different to P<0.005. 
A 
B 
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The effect of an approximate IC50 concentration of MRS 2578, as determined from figure 
10, on ADP-evoked calcium responses is shown in figure 11. At a concentration of 0.3 
µM, MRS 2578 caused a significant reduction in the Emax of calcium responses generated 
by ADP, indicating that MRS 2578 is acting as a non-competitive inhibitor for ADP-
evoked calcium responses. A similar effect was found elsewhere by Mamedova et al. 
(2004) where 10 µM MRS 2578 was found to non-competitively inhibit UDP-induced 
accumulation of inositol phosphate in human P2Y6-transfected 1321N1 human 
astrocytoma cells.  
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Figure 12 – MRS 2500 had no significant effect on ADP-evoked calcium 
responses 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with a 
vehicle control or 1 µM MRS 2500 (A), or increasing concentrations of MRS 
2500 (B), before being challenged with 3 µM ADP. Shown are representative 
time-resolved traces (A) and the dose-response plot of the peaks of the 
calcium responses (B), represented in the form of F Ratio (340/380), with the 
data points representing mean ± SEM. N=3.  
 
A 
B 
 55 
 
P2Y1 is another P2Y receptor that is activated by ADP, and figure 12 shows the effect of 
using MRS 2500, a selective P2Y1 antagonist, on ADP-evoked calcium responses in THP-
1 monocytes. Based on a reported IC50 value for MRS 2500 of 0.95 nM for the inhibition 
of ADP-induced human platelet aggregation (Cattaneo et al., 2004), a concentration 
range of 1 – 3000 nM was used. None of the concentrations of MRS 2500 used had any 
notable effect on calcium responses induced by an approximate EC50 concentration of 
ADP. 
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Figure 13 – MRS 2211 only reduced ADP-evoked calcium responses at a 
supra-maximal concentration 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with a 
vehicle control or 30 µM MRS 2211 (A), or increasing concentrations of MRS 
2211 (B), before being challenged with 3 µM ADP. Shown are representative 
time-resolved traces (A) and a dose-response plot of the peaks of the calcium 
responses (B), represented in the form of F Ratio (340/380), with the data 
points representing mean ± SEM. N=3. * P<0.05 vs. 3 µM ADP + vehicle control. 
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P2Y13, like P2Y12, is a Gi-coupled ADP receptor, and so establishing the role of this 
receptor in ADP-evoked calcium responses would be useful. However, from a 
concentration range of MRS 2211, a P2Y13 antagonist, only the top concentration of 30 
µM caused significant inhibition of ADP-evoked calcium responses (figure 13). Since it 
has been found in other studies that MRS 2211 was observed to have a pIC50 of 5.97 
when inhibiting 100 nM ADP-induced IP3 production in 1321N1 cells (Kim et al., 2005), 
the inhibitory effect of 30 µM MRS 2211 on ADP-evoked calcium responses in THP-1 
cells is likely non-specific. This suggests that MRS 2211 does not affect ADP-evoked 
calcium responses in THP-1 cells. 
 
In summary of the findings from figures 10 – 13, the inhibitor for P2Y6, but not the 
inhibitors for P2Y1 and P2Y13, caused a decrease in ADP-evoked calcium responses. 
Therefore, overall the results in this chapter suggest that calcium responses induced by 
ADP are dependent on activation of P2Y12 and P2Y6. However, the selectivity of the 
antagonists used must be considered, and the selectivity of the P2Y12 inhibitors 
ticagrelor and PSB-0739 is studied in the next section.  
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3.4 - Investigating the pharmacological selectivity and characteristics of 
ticagrelor and PSB-0739 
3.4.1 – Introduction & Aim 
Both of the P2Y12 antagonists used in this investigation, ticagrelor and PSB-0739, are 
reported to be selective for binding to P2Y12 over other receptors. Ticagrelor was shown 
to reduce thrombus formation in P2Y12-positive mice in a murine laser-injury model to 
levels found in P2Y12-negative mice, but no reduction in thrombus formation occurred 
in ticagrelor-treated P2Y12-deleted mice (Patil et al., 2007). PSB-0739 (30 nM and 1 µM) 
was shown in CHO Flp-In cells stably expressing recombinant human P2Y13 not to block 
the effect of 2-methylthio-ADP in inhibiting forskolin-induced increases in cellular 
cAMP. Furthermore, 1 µM PSB-0739 caused minor, or no effect on the stimulation of the 
recombinant human P2Y1, P2Y11 or P2Y14 receptors stably expressed in 1321N1 cells 
(Hoffmann et al., 2009). Although there is previous evidence for selectivity of ticagrelor 
and PSB-0739 in certain experiments, it was valuable to investigate their selectivity at 
P2Y12 in the type of experiments performed in this study, calcium experiments, in THP-1 
cells. Experiments involving P2Y12 and P2Y6 antagonists indicated that ADP-evoked 
calcium responses are dependent on activation of P2Y12 and P2Y6, so it was important 
to establish whether the two P2Y12 antagonists used were in fact selective for P2Y12 
over P2Y6.  
 
In addition to P2Y12 inhibition, ticagrelor has been reported to also cause inhibition of 
the equilibrative nucleotide transporter-1 (ENT-1), preventing adenosine uptake into 
the cell and therefore resulting in extracellular accumulation of adenosine. It was 
observed here that concentrations of ticagrelor greater than 5 µM caused an increase in 
resting baseline Ca2+, which may be due to adenosine accumulation. Therefore, another 
aim in this section was to determine whether high concentrations of ticagrelor caused 
increasing baseline Ca2+ concentration due to an adenosine-mediated effect, or because 
of a different effect.  
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3.4.2 - Results 
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Figure 14 – Ticagrelor has no significant effect on ADP-evoked 
calcium responses in hP2Y6-overexpressing 1321N1 cells 
Fura-2-loaded hP2Y6-overexpressing 1321N1 astrocytomas were pre-
incubated with a vehicle control or 3 µM ticagrelor (A), or increasing 
concentrations of ticagrelor (B), before being challenged with 3 µM ADP. 
Shown are representative time-resolved traces (A) and an inhibitory dose 
response plot of the peaks of the calcium responses (B), represented in the 
form of F Ratio (340/380), with the data points representing mean ± SEM. 
N=3. 
A 
B 
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Human P2Y6-overexpressing 1321N1 astrocytomas were used to help determine 
whether the P2Y12 antagonists used in this study had any affect at the P2Y6 receptor, 
therefore giving insight into how selective the antagonists are. ADP-induced calcium 
responses in these cells were not significantly affected when pre-incubated with 
ticagrelor, as seen from figure 14. In regular THP-1 cells ticagrelor caused a dose-
dependent effect on ADP-evoked calcium responses, but this was not evident in P2Y6-
overexpressing 1321N1 cells. 
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Figure 15 – Ticagrelor causes partial reduction of an ADP-evoked dose-
response curve in hP2Y6-overexpressing 1321N1 cells, but causes no 
significant Emax inhibition 
Fura-2-loaded hP2Y6-overexpressing 1321N1 astrocytomas were pre-
incubated for 30 mins with 5 µM ticagrelor or vehicle control before being 
challenged with 30 µM ADP (A), or increasing concentrations of ADP (B). 
Shown are representative time-resolved traces (A) and dose response curves 
of the peaks of the calcium responses (B), represented in the form of F Ratio 
(340/380), with the data points representing mean ± SEM. N=3. * denotes 
P<0.05, as determined by a paired student’s t-test. 
A 
B 
 
 62 
 
The IC50 concentration of ticagrelor for inhibiting ADP-evoked calcium responses in 
THP-1 cells, 5 µM, was commonly used in this investigation in several experiments. 
Therefore, it was useful to know the effect of this ticagrelor concentration on ADP-
evoked calcium responses in P2Y6-overexpressing 1321N1 cells, this is shown in figure 
15. Ticagrelor at 5 µM did cause significant decreases in calcium responses evoked by 1 
µM and 0.3 µM ADP, and a reduction in the sustained phase of the calcium response to 
30 µM ADP, which is also observed in standard THP-1 cells. Ticagrelor however had no 
significant effect on the Emax of the dose-response curve. Consequently, unlike what was 
found in THP-1 cells, ticagrelor does not cause non-competitive inhibition of ADP-
evoked calcium responses in P2Y6-overexpressing 1321N1 astrocytomas, which is the 
reported mode of action for this antagonist. This reinforces the findings from figure 14, 
and taken together these results indicate that ticagrelor is selective at P2Y12 over P2Y6. 
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Figure 16 – PSB-0739 reduces ADP-evoked calcium responses in a 
dose-dependent manner in hP2Y6-overexpressing 1321N1 cells 
Fura-2-loaded hP2Y6-overexpressing 1321N1 astrocytomas were pre-
incubated for 30 mins with a vehicle control or 25 µM PSB-0739 (A), or 
increasing concentrations of PSB-0739 (B), before being challenged with 3 µM 
ADP. Shown are representative time-resolved traces (A) and an inhibitory 
dose response curve of the peaks of the calcium responses (B), represented in 
the form of F Ratio (340/380), with the data points representing mean ± SEM. 
PSB-0739 IC50 = 2.96 µM ± 0.4. N=3. * P<0.05 vs. 3 µM ADP + vehicle control. 
A 
B 
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P2Y6-overexpressing 1321N1 cells were also used to determine the selectivity for the 
P2Y12 antagonist PSB-0739 at P2Y12 over P2Y6. When the effect of PSB-0739 on 3 µM 
ADP-evoked calcium responses was investigated, 10 and 25 µM PSB-0739 caused 
significant reduction in ADP-induced calcium responses, as presented in figure 16. 
Although there was no progressive inhibitory dose-response trend as seen in THP-1 
cells (figure 8), an IC50 value of 2.96 µM was still obtained for P2Y6-overexpressing 
1321N1 cells, which is very similar to that obtained in THP-1 cells. Therefore, the 
results from figure 14 suggest that PSB-0739 does cause reduction of ADP-evoked 
calcium responses in a dose-dependent manner in P2Y6-overexpressing 1321N1 
astrocytoma cells.  
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Figure 17 – 10 µM PSB-0739 caused a competitive inhibition of ADP-
evoked calcium responses in hP2Y6-overexpressing 1321N1 cells 
Fura-2-loaded hP2Y6-overexpressing 1321N1 astrocytomas were pre-
incubated for 30 mins with 5 or 10 µM PSB-0739 or a vehicle control before 
being challenged with 3 µM ADP (A), or increasing concentrations of ADP. 
Shown are representative time-resolved traces (A) and dose response curves 
of the peaks of the calcium responses (B), represented in the form of F Ratio 
(340/380), with the data points representing mean ± SEM. The data was 
normalised to the highest value generated from all repeats across the 
treatments. N=3. ‘ADP + vehicle control’ EC50 = 4.02 µM. ‘ADP + 5 µM PSB-
0739’ EC50 = 4.37 µM. ‘ADP + 10 µM PSB-0739’ EC50 = 21.44 µM. EC50 values 
in (B) between the effect of 10 µM PSB-0739 vs. vehicle control are 
significantly different to P<0.05. 
A 
B 
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Figure 17 shows that 10 µM, but not 5 µM, PSB-0739 caused a significant increase in 
the EC50 obtained for peak calcium responses evoked by a concentration range of ADP in 
P2Y6-overexpressing 1321N1 cells. Surprisingly, 5 µM PSB-0739 significantly 
potentiated calcium responses induced by 10 µM and 30 µM, however as PSB-0739 has 
been widely reported as a competitive antagonist, comparing the overall EC50 is a more 
reliable measure of effectiveness. The results from this figure and figure 16 are 
comparable with those from when the effect of PSB-0739 on ADP-evoked calcium 
responses was determined in THP-1 cells (figures 8 & 9). Overall, it can be concluded 
that PSB-0739 causes inhibition of ADP-evoked calcium responses in both THP-1 cells 
and P2Y6-overexpressing 1321N1 cells, indicating that PSB-0739 is not selective at 
P2Y12 over P2Y6.  
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Figure 18 – Ticagrelor increases cytosolic Ca2+ in a dose-dependent 
manner 
Fura-2-loaded THP-1 monocytes were challenged with a vehicle control or 
increasing concentrations of ticagrelor. Shown are the representative 
traces of the calcium responses, represented in the form of F Ratio 
(340/380), with the data points representing mean ± SEM. * denotes 
P<0.05, as determined by a paired student’s t-test of endpoint values when 
compared to vehicle control. N=3. 
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It was observed that ticagrelor concentrations at 10 µM or higher caused an increase in 
the resting Ca2+ concentration before applying the nucleotide agonist, as seen by the 
‘loading’ value from the SoftMax Pro software. Therefore, experiments using ticagrelor 
at concentrations of 10 µM or above were performed (Figure 18), which showed that 
ticagrelor, at these concentrations, does indeed cause an elevation of baseline calcium in 
a dose-dependent manner. This elevation of cytosolic calcium may be contributing to 
the inhibitory effect of ticagrelor. The effect of 10 µM ticagrelor on baseline Ca2+ is 
investigated further, however 5 µM ticagrelor was the concentration that was most 
commonly used as an inhibitory concentration in this study, and this concentration was 
shown not to cause an increase in cytosolic Ca2+.  
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A potential explanation for ticagrelor-mediated Ca2+ elevation could be given by the fact 
that ticagrelor has previously been found to cause inhibition of the ENT-1 transporter 
protein. Therefore, ticagrelor may prevent uptake of adenosine back into the cell, 
causing activation of adenosine receptors and subsequent elevation of cytosolic Ca2+. In 
an attempt to replicate this potential mechanism, the effect of an ENT-1 inhibitor 
nitrobenzylmercaptopurineriboside (NBMPR) was determined, as demonstrated in 
figure 19. It has been shown in another study that NBMPR caused inhibition of uridine 
influx in Xenopus oocytes expressing human ENT-1 with an IC50 of 3.6 nM ± 1.4 (Yao et 
al., 1997), which was used as a guide here to decide on a maximal NBMPR 
concentration. NBMPR does not raise the baseline calcium level in a similar fashion to 
ticagrelor, indicating that ticagrelor-induced cytosolic Ca2+ elevation is not due to 
inhibition of ENT-1.  
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Figure 19 – The ENT-1 inhibitor NBMPR does not increase cytosolic Ca2+ 
Fura-2-loaded THP-1 monocytes were challenged with 10 or 3 µM NBMPR. 
Shown are the representative traces of the calcium responses, represented in the 
form of F Ratio (340/380), with the data points representing mean ± SEM. N=3.  
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Figure 20 – The ENT-1 inhibitor NBMPR has no effect on ADP evoked 
calcium responses 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 3 µM 
NBMPR or a vehicle control before being challenged with 30 µM ADP. Shown 
are the representative traces of the calcium responses, represented in the 
form of F Ratio (340/380), with the data points representing mean ± SEM.  
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Figure 20 shows that 3 µM NBMPR had no effect on calcium responses evoked by 30 
µM ADP, suggesting that inhibition of ENT-1 has no effect on ADP-evoked calcium 
responses. Overall, the results from figures 19 and 20 indicate that elevation of baseline 
calcium caused by ticagrelor at 10 µM or above is not due to ENT-1 inhibition. It was 
observed through light microscopy that 30-minute pre-incubation with 10 µM 
ticagrelor or above caused a decrease in the number of visible THP-1 cells, when 
compared to cells preincubated with 5 µM ticagrelor or lower. This indicates that 
ticagrelor causes cell death at higher concentrations of 10 µM or above. Further study is 
required into the other effects of ticagrelor observed here at higher concentrations. In 
this study, however, as 5 µM ticagrelor is the maximum concentration that has been 
used, effects of ticagrelor at 10 µM or above has no impact on the results found here 
using the drug. 
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3.5 - Using siRNA in THP-1 monocytes to determine the effect of P2Y12 
knockdown on ADP-evoked calcium responses 
3.5.1 - Introduction & Aim 
Findings from previous experiments in this investigation have indicated that ADP-
evoked calcium responses in THP-1 cells are dependent on activation of P2Y12. 
However, these conclusions were entirely drawn from experiments looking at the effect 
of pharmacological inhibitors on ADP-evoked calcium responses. Although experiments 
were conducted in this study to investigate the selectivity of the P2Y12 inhibitors used, 
there is still the possibility that the antagonists used here are not selective. Therefore, a 
more certain method for inhibiting P2Y12 in ADP-evoked calcium responses in THP-1 
cells would strengthen the suggested conclusions here. Small-interfering RNA (siRNA) 
are commonly used for transient gene-silencing due to their role in causing post-
transcriptional degradation of targeted mRNA.  
 
P2Y12-targeted siRNA is used here in an attempt to cause a transient knockdown of 
P2Y12 in THP-1 monocytes, hence providing a more reliable experiment for a reduction 
in P2Y12 activity than simply assessing the effect of pharmacological P2Y12 inhibitors. 
This helps to provide stronger conclusions about the role of P2Y12 in mediating ADP-
evoked calcium responses in THP-1 monocytes.  
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3.5.2 - Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P2Y12 GAPDH -VE control
0.0
0.1
0.2
0.3
0.4
M
e
a
n
 P
e
a
k
 F
 R
a
ti
o
 (
3
4
0
/3
8
0
) 
(n
o
rm
a
lis
e
d
 t
o
 I
o
n
o
m
y
c
in
)
siRNA Treatment
*
 
Figure 21 – P2Y12-targeted siRNA significantly decreased ADP-
evoked calcium responses in THP-1 cells. 
THP-1 monocytes were transfected with 25 nM P2Y12-targeted, GAPDH-
targeted (positive control), or negative-control siRNA using DharmaFECT 2 
transfection reagent for 48 hrs as outlined in Materials & Methods. 2x105 
cells/well were then loaded before being challenged with 3 µM ADP, or 1 
µM ionomycin. Ionomycin responses were used to normalise for any 
differences in cell number. Shown is a bar chart representing the peak size 
of the calcium responses, represented in the form of F Ratio (340/380), 
with the data points representing mean ± SEM. N=3. * P<0.05. 
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ADP-evoked calcium responses were measured in THP-1 cells transfected with siRNA 
targeted to P2Y12, and were compared to those in THP-1 cells transfected with GAPDH-
targeted siRNA or negative control siRNA. As figure 21 shows, THP-1 cells transfected 
with P2Y12-targeted siRNA exhibited significantly smaller calcium responses to ADP-
induced calcium responses, compared to the controls. These results support the 
previous findings in this study that suggest that P2Y12 is involved in mediating ADP-
evoked calcium responses in THP-1 cells.  
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Figure 22 – P2Y12-targeted and GAPDH-targeted siRNA caused 
knockdown of over 40% in the respective mRNA. 
THP-1 monocytes were transfected with 25 nM P2Y12-targeted, GAPDH-
targeted (positive control), or negative-control siRNA using DharmaFECT 2 
transfection reagent for 48 hrs with the method outlined in Materials & 
Methods. The same respective populations of cells used for figure 21 were 
used here. mRNA expression was determined using Taqman probes with 
the qRT-PCR method described in Materials and Methods. Shown is a bar 
chart representing the relative quantifications of mRNA, as calculated using 
the ∆∆CT method, with the data points representing mean ± SEM. N=3. The 
mean of B2M and GAPDH mRNA was used as housekeeping genes during 
the ∆∆CT method. 
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Although the results in figure 21 show that P2Y12-targeted siRNA causes a reduction in 
ADP-evoked calcium responses, it was also necessary to measure the gene expression of 
P2Y12 in the same populations of cells as those used for the calcium experiments. This is 
important as it would show whether the reduction in calcium responses in THP-1 cells 
treated with P2Y12-targeted siRNA correlates with a reduction in gene expression, 
which should be the case. Figure 22 demonstrates that, compared to the scrambled 
negative control, there was over a 40% reduction in both P2Y12 and GAPDH mRNA in 
THP-1 cells treated with siRNA targeted to P2Y12 and GAPDH respectively.  
 
The results in this chapter suggest that molecular knockdown of the P2Y12 receptor 
causes a reduction in calcium responses evoked by ADP. This strongly indicates that 
P2Y12 is involved in mediating ADP-evoked calcium responses in THP-1 cells, which 
supports the similar conclusions made previously in this investigation.   
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3.6 - Discovery of a potential signalling transduction mechanism behind ADP-
evoked calcium responses in THP-1 monocytes 
3.6.1 - Introduction & Aim 
The results shown thus far indicate that ADP-evoked calcium responses in THP-1 
monocytes are dependent on activation of both P2Y12 and P2Y6, indicating that P2Y12 
contributes to calcium responses evoked by ADP in these cells.  
It is important to attempt to understand the signalling mechanism behind the 
involvement of P2Y12 in ADP-induced calcium responses, and whether there is a cross-
talk mechanism behind P2Y12 and P2Y6 in mediating the calcium responses evoked by 
ADP in THP-1 monocytes.  
 
ADP activates P2Y purinergic receptors, such receptors being G protein-coupled 
receptors (GPCRs). The downstream signalling pathway following GPCR activation 
depends on the type of G protein in question. For instance, P2Y6 is coupled to a Gq 
protein, which causes hydrolysation of phosphatidylinositol 4,5-bisphosphate (PIP2) 
into diacyl glycerol (DAG) and inositol trisphosphate (IP3) through activation of 
phospholipase C (PLC). Subsequent IP3 generation causes release of calcium ions from 
the endoplasmic reticulum (ER). Conversely, the effects of Gi, the G protein coupled to 
P2Y12, include inhibition of adenylate cyclase, resulting in decreased cytosolic cAMP 
concentration, and activation of phosphoinositide 3-kinase (PI3K). Subsequently, by 
using selective antagonists for some of the proteins involved in these transduction 
pathways, valuable insight would be gained into the nature of ADP-evoked calcium 
responses described previously. 
 
Since P2Y12 is Gi-coupled, and therefore unlikely to cause calcium mobilisation, the 
receptor may be modulating the calcium response evoked by a Gq-coupled P2Y receptor, 
for exampleP2Y6. A cross-talk mechanism has been reported between Gq-coupled P2Y1 
and Gi-coupled P2Y12 in platelets whereby P2Y12 potentiates the P2Y1-mediated ADP-
evoked calcium response through inhibition of adenylate cyclase and activation of PI3K 
(Hardy et al., 2004). Since in THP-1 cells ADP-induced calcium responses have been 
shown to be dependent on P2Y6 activation as well as P2Y12, a similar mechanism to the 
P2Y1-P2Y12 cross-talk in platelets, but for P2Y6 and P2Y12 in THP-1 monocytes.  
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Overall, the experiments in this section attempted to determine the signalling 
transduction mechanism behind ADP-evoked calcium responses in THP-1 monocytes 
and investigate any potential crosstalk mechanism between P2Y12 and P2Y6. This is 
achieved by assessing the effect of selective inhibitors for certain proteins implicated in 
different stages of the relevant signalling transduction pathways on ADP-evoked 
calcium responses.  
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3.6.2 - Results 
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Figure 23 – ADP-evoked calcium responses are sensitive to the PI3K 
inhibitor LY294002 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 30 
or 100 µM LY294002 or a vehicle control before being challenged with 30 
µM ADP. Shown are the representative traces of the calcium responses, 
represented in the form of F Ratio (340/380), with the data points 
representing mean ± SEM. N=3. * denotes P<0.005 and ** denotes P<0.001 
of peak values, as determined by a paired student’s t-test. 
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Figure 23 shows the effect of a PI3K inhibitor on ADP-evoked calcium responses. 
Calcium responses stimulated by a maximal concentration of ADP were significantly 
inhibited by the PI3K inhibitor LY294002, suggesting that ADP-evoked calcium 
responses are dependent upon PI3K activity and therefore dependent upon activation 
of a Gi-coupled receptor, due to Gi activation causing stimulation of PI3K. 
 
LY294002 has been shown, with an IC50 value of 1.4 µM, to negate PI3K activity, without 
causing inhibition of other protein or lipid kinases such as PI4K, PKC or MAP-kinase 
(Viahos et al., 1994), indicating that LY294002 is selective for PI3K. Conversely, PI4K 
inhibition, together with PI3K inhibition, was however observed in platelets treated 
with LY294002 (Rosado and Sage, 2000). However, the experiments in the study by 
Viahos et al. involved experiments in several different cell types, rather than platelets.  
 
A previous study showed that 50 µM LY294002 caused significant decrease in 
carbachol- or caffeine-evoked calcium transients in bovine aortic smooth muscle cells 
(Ethier and Madison, 2002), and these findings were used as an indicator for choosing a 
sensible LY294002 concentration for causing inhibition of PI3K. 
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The involvement of Gi protein activity in mediating ADP-stimulated calcium responses 
was further investigated by establishing the effect of the Gi inhibitor pertussis toxin. It is 
well established that CCR2, the receptor for CCL2, is Gi-coupled and can also elicit 
calcium responses when stimulated by CCL2. As a positive control for pertussis toxin 
fully functioning as a Gi protein blocker, the effect of pertussis toxin on CCL2-evoked 
calcium responses was determined, as shown in figure 24. Pertussis toxin, at 5 ng/µl, 
completely negated the CCL2-evoked calcium response, indicating that pertussis toxin is 
having a maximum effect at this concentration.  
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Figure 24 – The Gi protein blocker pertussis toxin (PTx) abolishes 
CCL2-evoked calcium responses in THP-1 monocytes 
Fura-2-loaded THP-1 monocytes were pre-incubated for 3 hours with 5 
ng/µl pertussis toxin or a vehicle control before being challenged with 50 
ng/ml CCL2. Shown are the representative traces of the calcium responses, 
represented in the form of F Ratio (340/380), with the data points 
representing mean ± SEM. N=3.  
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Figure 25 – The Gi protein blocker pertussis toxin (PTx) causes 
significant inhibition of an ADP-evoked dose-response 
Fura-2-loaded THP-1 monocytes were pre-incubated for 3 hours with 5 
ng/µl PTx or a vehicle control before being challenged with 3 µM ADP (A) 
or increasing concentrations of ADP (B). Shown are representative time-
resolved traces (A), and dose-response curves of the peaks of the calcium 
responses (B), represented in the form of F Ratio (340/380), with the data 
points representing mean ± SEM. ‘ADP + vehicle control’ EC50 = 1.87 µM ± 
0.33 Emax = 3.45 ± 0.07. ‘ADP + 5 ng/µl’ EC50 = 2.78 µM ± 0.21 Emax = 2.3 ± 
0.04. N=3. The respective EC50 and Emax of the different conditions in (B) are 
significantly different to P<0.05. 
A 
B 
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In figure 25, the effect of the Gi inhibitor pertussis toxin on calcium responses induced 
by ADP was assessed. Pertussis toxin caused significant increase of the EC50, and 
significant decrease in the Emax of an ADP-evoked dose-response curve. The 
concentration used here was equal to that used in figure 24, which demonstrated a 
positive control. These results indicate that calcium responses induced by ADP are 
dependent upon activation of Gi.  
 
In summary of the outcomes from figures 23 – 25, it is indicated that ADP-stimulated 
calcium responses in THP-1 monocytes are sensitive to pertussis toxin and the PI3K 
inhibitor LY294002, implying that activation of a Gi-coupled receptor is also involved in 
mediating the calcium response. Therefore, both Gq-, and Gi-coupled receptors are 
suggested to be involved in mediating the ADP-induced calcium response, potentially 
implicating a crosstalk mechanism between P2Y12 and P2Y6 in eliciting the calcium 
response. 
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In an attempt to investigate a potential crosstalk transduction mechanism for ADP-
evoked calcium responses involving adenylate cyclase (AC) inhibition, the 
pharmacological AC inhibitor SQ22536 was used. Before specifically looking at the 
involvement of P2Y12 in this hypothetical mechanism, it was important to test the effect 
of SQ22536 on ADP-evoked calcium responses alone as a negative control. Figure 26 
shows that SQ22536 had no effect on ADP-stimulated calcium responses alone in THP-1 
cells at 300 µM.  
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Figure 26 – The adenylate cyclase inhibitor SQ22536 has no effect on 
calcium responses induced by ADP alone. 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 300 
µM SQ22536 or a vehicle control before being challenged with 3 µM ADP. 
Shown are the representative traces of the calcium responses, represented 
in the form of F Ratio (340/380), with the data points representing mean ± 
SEM. N=3.  
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Figure 27 – The adenylate cyclase inhibitor SQ22536 restores ADP-
evoked calcium responses inhibited by ticagrelor  
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 5 µM 
ticagrelor with or without 300 µM SQ22536 or a vehicle control before 
being challenged with 3 µM ADP. Shown are the representative traces of the 
calcium responses, represented in the form of F Ratio (340/380), with the 
data points representing mean ± SEM. N=3. * indicates significance between 
the peak vs ‘3 µM ADP + vehicle control, P<0.05. 
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To determine whether P2Y12 could be involved in ADP-induced calcium responses 
through AC inhibition, the effect of SQ22536 on ADP-evoked calcium responses 
inhibited by either ticagrelor or PSB-0739 was established. Figure 27 illustrates that 
ADP-evoked calcium responses inhibited by ticagrelor are significantly increased when 
in the presence of SQ22536, compared to when SQ22536 is not present. This suggests 
that P2Y12 may be involved in mediating ADP-induced calcium responses through 
inhibition of adenylate cyclase. It was determined in human blood platelets that a 3-6-
fold increase in adenylate cyclase activity by prostaglandin E1 was inhibited in a dose-
dependent manner by SQ22536, with an IC50 value of 21 µM (Harris et al., 1979), with 
this value serving as an aid in determining a suitable SQ22536 concentration for this 
experiment.  
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Figure 28 – The adenylate cyclase inhibitor SQ22536 significantly 
increases the Emax of an ADP-evoked dose response curve inhibited 
by ticagrelor 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 5 
µM ticagrelor with or without 300 µM SQ22536 or a vehicle control before 
being challenged with increasing concentrations of ADP. Shown are the 
dose response curves of the peaks of the calcium responses, represented 
in the form of F Ratio (340/380), with the data points representing mean 
± SEM. ‘ADP + vehicle control’ Emax = 3.25 ± 0.18, ‘ADP + 5 µM ticagrelor + 
300 µM SQ22536’ Emax = 2.59 ± 0.14, ‘ADP + 5 µM ticagrelor’ Emax = 1.03 ± 
0.12. N=3. The Emax of ‘ADP + 5 µM ticagrelor’ vs. ‘ADP + vehicle control’ is 
significantly different to P<0.05. 
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To reinforce the results from figure 27, it was assessed whether SQ22536 would cause 
any recovery of the ticagrelor-induced reduction in Emax of an ADP-evoked dose 
response curve. The AC inhibitor SQ22536 significantly increased the Emax value of an 
ADP-induced dose-response curve inhibited by the presence of ticagrelor in THP-1 cells, 
compared to just ticagrelor pre-treatment alone. As previously described, the reported 
mechanism of inhibition of ticagrelor is non-competitive, which is shown again here by 
the decrease in Emax. Since SQ22536 lessened the ticagrelor-mediated non-competitive 
inhibition of ADP-evoked calcium responses, these results further suggest that P2Y12 
may be contributing to ADP-stimulated calcium responses via inhibition of adenylate 
cyclase.  
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Figure 29 – The adenylate cyclase inhibitor SQ22536 significantly 
increases ADP-evoked calcium responses inhibited by PSB-0739 
Fura-2-loaded THP-1 monocytes were pre-incubated for 30 mins with 5 
µM PSB-0739 with or without 300 µM SQ22536 or a vehicle control before 
being challenged with 3 µM ADP. Shown are the representative traces of 
the calcium responses, represented in the form of F Ratio (340/380), with 
the data points representing mean ± SEM. N=3. The difference between 
the peak of ‘3 µM ADP + 5 µM PSB-0739’ vs. ‘3 µM ADP + vehicle control’ is 
significant to P<0.05. 
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The experiment conducted for figure 27 was repeated, only using PSB-0739 instead of 
ticagrelor as a P2Y12 inhibitor, with the results shown in figure 29. PSB-0739 caused a 
significant decrease in calcium responses induced by an approximate EC50 
concentration of ADP (3 µM), however SQ22536 caused significant increase of ADP-
evoked calcium responses inhibited by PSB-0739. These results support the findings 
from figures 27 and 28, which suggest that ADP-induced calcium responses are 
dependent on P2Y12 activation because of P2Y12-mediated adenylate cyclase inhibition. 
The increase in ADP-induced calcium responses by SQ22536 observed in figures 27-29 
is indicated to be due to the presence of the respective P2Y12 inhibitor and not simply 
SQ22536 having an effect itself, as the negative control in figure 26 showed no effect of 
SQ22536 on ADP-evoked calcium responses alone.  
 
Overall, the results in this chapter indicate that calcium responses evoked by ADP in 
THP-1 monocytes are dependent upon both Gq- and Gi-coupled receptor activation, with 
a potential crosstalk mechanism suggested whereby P2Y12 positively modulates a 
primarily P2Y6-mediated calcium response to ADP through inhibition of adenylate 
cyclase, together with activation of PI3K. 
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Chapter 4 - Discussion 
 
4.1 - The physiological significance of identifying a role for P2Y12 in ADP-
evoked calcium responses in monocytes 
Demonstrated in this study are novel findings identifying P2Y12 as being involved in the 
calcium response to ADP in THP-1 monocytes. Furthermore, evidence is given for the 
expression of P2Y12 in cell-line, and primary monocytes, when it had been previously 
established that P2Y12 expression is mainly attributed to platelets, glial cells, smooth 
muscle cells and endothelial cells (Cattaneo, 2006).  
 
There have been no published reports on the role of P2Y12 in monocyte function thus 
far, however the involvement of P2Y12 in macrophage chemotaxis was investigated by 
Kronlage et al., (2010). Stimulation of P2Y12 in macrophages was found to induce cell 
spreading with formation of lamellipodia, and inhibition of multiple purinergic 
receptors, including P2Y12, blocked macrophage chemotaxis (Kronlage et al., 2010). It 
was indicated from these findings that collaborative autocrine signalling of purinergic 
receptors, such as P2Y12 and P2Y2, ensure directional motility of macrophages upon 
exposure to chemotactic gradients (Kronlage et al., 2010).  
 
ADP released from E. coli-infected mice, and from macrophages exposed to 
lipopolysaccharide (LPS), protected mice from E. coli-induced peritonitis via 
macrophage recruitment (Zhang et al., 2016). Additionally, ADP caused production of 
CCL2, a crucial chemokine in immune cell recruitment, which accordingly attracted 
more macrophages in a transwell assay (Zhang et al., 2016). Inhibition of downstream 
P2Y12 signalling, or macrophage P2Y12 deficiency, blocked immune responses to ADP, in 
turn allowing more bacteria to persist in infected mice (Zhang et al., 2016). This 
investigation by Zhang et al. revealed that upon sensing danger, macrophages release 
ADP, which binds to receptors such as P2Y12, mediating actions such as chemokine 
release and consequent recruitment of immune cells.  
Such findings may implicate ADP and P2Y12 as being crucial in forming a comprehensive 
immune response to infectious disease. 
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P2Y12 was shown to be expressed in dendritic cells also, and calcium responses to ADP 
in these cells was blocked by the P2Y12 antagonist AR-C69931MX (Ben Addi et al., 
2010). Subsequently, ADP-evoked calcium responses were entirely abolished in P2Y12-
deficient dendritic cells (Ben Addi et al., 2010). Moreover, results presented by Ben Addi 
et al. (2010) suggested that P2Y12 activation increased antigen uptake and subsequent 
activation of T cells. Hence, this study indicated that ADP-induced calcium responses in 
dendritic cells are dependent on P2Y12, and that this receptor is involved in immune 
cellular functions. Since macrophages and dendritic cells are derived from monocytes, 
the findings presented here and in other studies indicate that P2Y12 may also play a role 
in the physiological role of monocytes and therefore it would be useful for a functional 
investigation of P2Y12 in monocytes to take place.  
 
There is evidence to suggest that ADP contributes to the function of monocytes. For 
example, in the same cell-line used in this investigation, THP-1, ADP stimulation caused 
release of the cytokine tumour necrosis factor alpha (TNF-α) (Mattana et al., 2002). 
TNF-α release causes an inflammatory innate immune response including immune cell 
recruitment. In addition, ADP has been shown in this investigation to induce calcium 
signals in THP-1 cells, and calcium signalling in circulating monocytes has in fact been 
suggested to result in the development of mature dendritic cells (Czerniecki et al., 
1997). Such examples indicate that ADP contributes to monocyte function, with specific 
reference to immune responses and differentiation.  
 
In summary of previous studies, P2Y12 has been indicated in similar cell types to 
monocytes to have roles in mediating ADP-evoked calcium responses and also in 
physiological ADP-induced immune functions such as chemotaxis and antigen uptake. 
Although the role of P2Y12 has not been specifically studied in monocytes themselves, it 
has been suggested that ADP and calcium signalling modulates functional responses in 
such cells. Taken together with aforementioned reports, the current investigation, 
which has indicated that P2Y12 positively modulates THP-1 ADP-evoked calcium 
responses, therefore implies that P2Y12 may have a functional role in monocyte 
physiology.  
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Furthermore, monocytes are implicated in crucial early stages of atherosclerosis, in 
which they are recruited to the artery endothelium and subsequently migrate into the 
intima, where they differentiate into macrophages (Galkina and Ley, 2009). The 
presence of P2Y12 may be contributing to such pathogenic processes of monocytes in 
atherosclerosis, particularly when one considers that vessel wall P2Y12 has been 
indicated to contribute to early atherogenesis (West et al., 2014). Also, recent reports 
have shown that mice supplemented with ticagrelor developed more stable 
atherosclerotic plaques, as characterised by a reduced necrotic core and a thickening of 
the fibrous cap (Preusch et al., 2016). Moreover, in vitro experiments revealed that 
ticagrelor inhibits oxidised LDL uptake and reduces apoptosis in serum-starved 
macrophages from the RAW 264.7 cell-line (Preusch et al., 2016), indicating that 
ticagrelor may promote plaque stability through macrophage P2Y12 interaction. The 
results from studies by West et al. (2014) and Preusch et al. (2016) imply that P2Y12 
may have platelet-independent roles in vascular disease which need further study. This 
is made more relevant now since P2Y12 has been shown here to be involved in 
monocyte responses to ADP, with monocytes having highly important atherogenic 
functions.  
 
4.2 - A potential crosstalk mechanism between P2Y12 and P2Y6 in mediating 
ADP-evoked calcium responses in human monocytes 
In using a combination of pharmacological inhibitors and siRNA-mediated P2Y12 
knockdown, the findings in this project have strongly suggested that ADP-evoked 
calcium responses in THP-1 monocytes are dependent on P2Y12 activation. P2Y12 has 
been shown to be Gi-coupled (Hollopeter et al., 2001), but there have been no reported 
findings thus far to indicate that Gi-coupled purinergic P2Y receptors such as P2Y12 
directly elicit calcium responses when activated by extracellular stimuli. This is owing 
to the fact that activation of Gi does not classically cause IP3 production and therefore 
does not lead to release of Ca2+ from the ER. Therefore, how P2Y12 may be contributing 
to the stimulation of the calcium response was also investigated.  
Activation of platelets by ADP occurs through activation of P2Y1 and P2Y12, with P2Y1 
stimulation giving rise to Gq-mediated activation of PLC and a subsequent calcium 
response (Jin et al., 1998). Knockdown or pharmacological inhibition of P2Y1 has been 
shown in previous studies to abolish ADP-evoked calcium responses in platelets, and for 
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this reason it is accepted that P2Y1 is categorically required for ADP-induced calcium 
responses in these cells (Jin et al., 1998). However, it has also been demonstrated that 
P2Y1 is not solely responsible for eliciting the calcium response to ADP, with some 
studies showing P2Y12 to be implicated in modulating the response also (Fox et al., 
2004).  
 
It was discovered in platelets by Hardy et al. (2004) that the selective pharmacological 
P2Y12 inhibitor AR-C69931MX partially blocked the calcium response to 10 µM ADP, 
which was also shown to be completely abolished by selective P2Y1 inhibition. This 
suggested that P2Y12 is able to positively modulate the P2Y1-mediated calcium response 
to ADP in platelets. Subsequently, Hardy et al. identified that the PI3K inhibitor 
LY294002 (10 µM) partially inhibited the P2Y12-dependent part of the calcium response 
to ADP. Moreover, the adenylate cyclase inhibitor SQ22536 partially restored ADP-
evoked calcium responses in the presence of the P2Y12 inhibitor AR-C69931MX (Hardy 
et al., 2004). Taken together, these findings by Hardy et al. indicated in platelets that 
P2Y12 regulates P2Y1-mediated calcium responses to ADP through activation of PI3K 
and inhibition of adenylate cyclase.  
The findings in this investigation suggest that, of the ADP-activated P2Y receptors, ADP-
induced calcium responses in THP-1 cells are dependent on P2Y12 and P2Y6 activation, 
but not dependent on P2Y1 or P2Y13. Subsequently it would be logical that P2Y12 may be 
potentiating the P2Y6 Gq-mediated calcium response, without stimulation of both 
receptors being required. In further investigation of this potential mechanism, it was 
indicated in THP-1 cells that P2Y12 may modulate the P2Y6-mediated response through 
PI3K activation and inhibition of adenylate cyclase. The basic principle identified by 
Hardy et al. (2004) is supported here, only with P2Y6 acting as the equivalent of P2Y1. A 
proposed signalling transduction mechanism for how P2Y12 supports the P2Y6-
mediated calcium response to ADP in THP-1 cells is illustrated and explained in figure 
30. An interesting observation from this study was that P2Y1, although expressed at the 
gene level in THP-1 cells, seemingly was not involved in ADP-evoked calcium responses 
in THP-1 cells. This may be explained by the fact that mRNA expression does not always 
correlate with respective protein levels, so P2Y1 protein expression would need to be 
determined in THP-1 cells to further investigate this finding.  
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The cAMP pathway may decrease the concentration of Ca2+ by stimulating the plasma 
membrane calcium ATP-ase (PMCA) channel to remove Ca2+ from the cell (Suplat et al., 
2007), therefore limiting the magnitude of calcium responses. 
The exact mechanism as to how PI3K may contribute to the P2Y12-dependent 
potentiation of ADP-evoked calcium responses would still need to be investigated. One 
possibility could be that receptor-associated PI3K causes generation of PIP3, recruiting 
PLCγ and subsequently generating IP3, which releases calcium ions (Rameh et al., 
1998). An important point to consider is that the respective adenylate cyclase and PI3K 
pathways outlined above are suggested to be separate and are therefore not dependent 
on each other, but happen to both be activated by P2Y12 stimulation.  
 
 
 
 
Figure 30 – A hypothetical crosstalk 
mechanism between P2Y12 and 
P2Y6 in mediating an ADP-evoked 
calcium response 
When P2Y12 is inhibited, by ticagrelor 
for example (A), adenylate cyclase is 
not inhibited and causes increased 
cAMP levels. The cAMP-stimulated 
pathway lowers intracellular Ca2+ 
concentration, limiting the size of 
subsequent P2Y6-mediated calcium 
response. In normal circumstances 
however (B), P2Y12 is activated, 
inhibits adenylate cyclase and hence 
reduces the subsequent limiting effect 
on resulting calcium responses. 
Furthermore, PI3K can be activated by 
P2Y12 (Dorsam and Kunapuli, 2004) 
and contributes to the calcium 
response through an as-yet unclear 
mechanism, with possibilities 
discussed. Overall, P2Y12 supports the 
P2Y6-mediated calcium response to 
ADP. 
A 
B 
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The findings demonstrated here are not the only example of potential purinergic 
receptor crosstalk. Indeed, glioma C6 cells are indicated to exhibit the same P2Y12-P2Y1 
crosstalk mechanism as that observed in platelets whereby P2Y12 positively modulates 
P2Y1-mediated calcium responses to ADP via adenylate cyclase inhibition and PI3K 
activation (Suplat et al., 2007). Intriguingly, Seo et al (2008). also reported the 
possibility of P2Y1-P2Y12 crosstalk in rat microglia interleukin-10 (IL-10) production, 
but with P2Y12 negatively regulating P2Y1 activity in this case. This was concluded on 
account of a P2Y12 antagonist (2meSAMP) or a Gi protein blocker (pertussis toxin) 
causing upregulation of IL-10 production following stimulation with an ADP analogue 
(Seo et al., 2008).  
 
It was identified in mice that simultaneous inhibition of multiple purinergic receptors, 
including P2Y12 and P2Y2, blocked chemotaxis of macrophages (Kronlage et al., 2010). 
However, mice with either P2Y12 or P2Y2 deficiency exhibited efficient chemotaxis 
(Kronlage et al., 2010), indicating that a combined parallel effort of purinergic 
receptors, including P2Y12 and P2Y2, may be required for proper chemotaxis of 
macrophages.  
 
Overall, the results from this present investigation support the previous ones described 
here which suggest that P2Y12, although Gi coupled, is involved in mediating cellular 
responses to ADP through crosstalk with another P2Y receptor. The cellular responses 
are not only at the level of calcium signalling, but are also, in some cases, functional 
responses such as cytokine production and chemotaxis, in several different cell types 
too. Subsequently, such growing evidence theoretically implicating a Gi-coupled 
receptor as playing a role in calcium responses means that it would be unwise in any 
future studies investigating G protein-coupled receptors to rule out Gi-coupled 
receptors as being involved in calcium responses. This notion is supported by reports 
that suggest PI3K activation could itself induce release of calcium ions through 
consequent PIP3 production, PLCγ recruitment and IP3 generation (Rameh et al., 1998. 
Bae et al., 1998), with Gi-coupled receptors indeed causing activation of PI3K (Dorsam 
and Kunapuli, 2004).   
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If the theory presented here regarding P2Y12-P2Y6 crosstalk in monocytes holds true, it 
would cause further complexity into any current or future theories for the role of P2Y6 
in monocytes. For instance, Campwala et al (2014). indicated that P2Y6 activation 
potentiates CCL2-evoked calcium signalling in monocytes, where it was found that 
pharmacological P2Y6 inhibition or stable P2Y6 knockdown attenuated chemotaxis and 
calcium responses to CCL2 in THP-1 cells. As stated however, P2Y12 may positively 
modulate P2Y6-mediated calcium responses to ADP, so P2Y12 could have contribution in 
the functional monocyte response to CCL2. This is significant as CCL2 (or MCP-1) is a 
chemoattractant cytokine which has a key role in recruiting monocytes to inflammatory 
sites upon injury or infection but is also implicated in inflammatory conditions such as 
atherosclerosis (Deshmane et al., 2009). 
 
It is stipulated here that upon P2Y12 inhibition the downstream signalling pathway 
stimulated by cyclic AMP (cAMP) causes an inhibitory effect on subsequent calcium 
responses to ADP via activation of plasma membrane calcium efflux pumps. 
Interestingly, a previous study suggested that not only does P2Y12 deficiency reduce 
macrophage immune responses to E. coli infection in mice, but cAMP analogues such as 
8-bromo-cAMP also reduced ADP-induced CCL2 production and protection against 
bacterial infection (Zhang et al., 2016). Although the simultaneous effect of both P2Y12 
deficiency and addition of cAMP was not investigated by Zhang et al. (2016), which 
would be a more definitive measure, the results show that there is a possibility that the 
mechanism proposed in this investigation may run true in macrophages. This notion 
should be investigated further as the crosstalk mechanism involving P2Y12, P2Y6 and 
cAMP hypothesised here may have significance in the function of immune responses.  
 
4.3 - Off-target effects of pharmacological P2Y12 inhibitors in THP-1 monocytes 
Ticagrelor is a clinically-administered reversible P2Y12 inhibitor that is used to treat 
patients with acute coronary syndromes by acting as a platelet aggregation inhibitor 
(Wallentin et al., 2009). It is widely accepted that in addition to P2Y12 inhibition, 
ticagrelor can also cause inhibition of the type 1 equilibrative nucleoside transporter 
(ENT-1) that allows intracellular transport of extracellular adenosine (Cattaneo et al., 
2014). Inhibition of ENT-1 by ticagrelor causes extracellular accumulation of adenosine, 
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which has been suggested to contribute to the inhibition of platelet function by 
ticagrelor through activation of adenosine receptors (Aungraheeta et al., 2016). 
 
In this study, it was observed that ticagrelor caused a gradual increase in calcium ion 
concentration when added as an agonist to THP-1 cells at concentrations of 10 µM or 
above. It was thought that this observation could be owing to the reported effect of 
ticagrelor causing accumulation of extracellular adenosine due to ENT-1 inhibition. 
However, upon investigation, further results indicated that use of an ENT-1 inhibitor 
did not cause a similar effect seen with ticagrelor treatment. This suggested that ENT-1 
inhibition was not responsible for the effect of high concentrations of ticagrelor on 
calcium in THP-1 cells. Furthermore, when looking at THP-1 cells after pre-treatment 
with ticagrelor at 10 µM or higher, smaller numbers of cells were identified compared to 
cells pre-treated with 5 µM or below. This suggested that ticagrelor may be causing cell 
death at higher concentrations in THP-1 cells, which is likely to be the reason behind the 
gradual increase in calcium ions upon treatment with higher ticagrelor concentrations. 
There are no previous reports of ticagrelor having cytotoxic effects at such 
concentrations, and these novel findings should be explored further due to the clinical 
role ticagrelor plays in medicine.  
 
Recent experiments investigating the effect of ticagrelor on endothelial calcium 
signalling found that ticagrelor (2-10 µM) caused an increase in intracellular calcium, 
which is suggested to have been from influx of calcium ions from the extracellular space, 
rather than intracellular calcium release from the ER (Gündüz et al., 2016). This is 
another possibility behind the increased intracellular calcium concentration induced by 
high ticagrelor concentrations, but would need further study as the nature of the 
suggested ticagrelor-evoked calcium influx effect presented by Gündüz et al. (2016) is 
unclear.  
 
It may be the case that ticagrelor has off-target or cytotoxic effects at certain 
concentrations, however ticagrelor had no effect on intracellular calcium at the 
concentrations used to investigate the role of P2Y12 in calcium responses to ADP. 
Therefore, such potential alternative effects of ticagrelor do not impact on the 
conclusions made here about P2Y12. Furthermore, ticagrelor was shown to be selective 
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for P2Y12 over P2Y6 at the concentrations used, reinforcing its use as a suitable 
pharmacological tool here.  
 
Previously it has been stated that P2Y12 is primarily expressed in platelets, glial cells, 
endothelial cells and smooth muscle cells (Cattaneo, 2006), but results demonstrated 
here indicating that the receptor is expressed in human monocytes broaden the scope 
regarding the expression of P2Y12 in the human body. As previously discussed in this 
chapter, there are growing reports identifying potential functional roles for P2Y12 in 
leukocytes, such as macrophages and dendritic cells. Together with this investigation, 
these findings may question the effects clinically-used antiplatelet drugs, such as the 
P2Y12 inhibitor ticagrelor, may be having on cells other than platelets when 
administered to patients. This is supported by a study involving patients receiving 
antiplatelet therapy, specifically the P2Y12 inhibitor clopidogrel, where it was 
demonstrated that clopidogrel reduced leukocyte activation, with the leukocytes also 
found to express P2Y12 (Diehl et al., 2009). This suggests that clopidogrel can act 
directly on leukocytes when administered, and not only on platelets. Hence, it would be 
wise to investigate any effects ticagrelor treatment has on leukocytes such as 
monocytes, dendritic cells and macrophages, as such clinically-used P2Y12 inhibitors 
may be having negative impacts on immune function. 
 
PSB-0739 is a pharmacological P2Y12 inhibitor that has been reported to be highly 
potent, and selective at P2Y12 over P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y13, P2Y14, P2X2, and 
P2X7 (Baqi et al., 2009). On the contrary to ticagrelor however, PSB-0739 was not found 
to be selective for P2Y12 over P2Y6 in this study, indicating that the effects of this 
antagonist on ADP-evoked calcium responses are not due to inhibition of P2Y12. Hence, 
conclusions about the role of P2Y12 in monocytes cannot be drawn from experiments 
involving PSB-0739, and it would be wise for future studies to take care drawing 
conclusions from experiments using PSB-0739 to study P2Y12. Nevertheless, in this 
investigation, experiments involving siRNA-mediated P2Y12 knockdown support the 
results from experiments investigating the effect of ticagrelor on calcium responses 
induced by ADP, signifying that overall there is strong evidence for P2Y12 involvement 
in ADP-evoked calcium responses.  
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4.4 - Conclusions 
The findings presented here suggesting that P2Y12 positively modulates ADP-evoked 
calcium responses in THP-1 monocytes broadens current knowledge in monocyte 
biology, subsequently having significance in expanding the current understanding the 
physiological function of monocytes in health and disease. Furthermore, an intricate 
crosstalk mechanism underpinning the involvement of P2Y12 in ADP-evoked calcium 
responses has been indicated, drawing parallels with similar observations in platelets 
and other cell types. Consequently, this advances current knowledge in downstream 
signal transduction of G protein-coupled receptor activation and may have implications 
in the function of the immune system. Investigations into the use of the pharmacological 
P2Y12 inhibitors used have implied that PSB-0739 may not be specific for P2Y12, and 
have also shed further light on alternative effects of ticagrelor other than P2Y12 
inhibition. Finally, it is suggested that the platelet-independent effects of ticagrelor must 
be considered following the results shown here and in other studies that demonstrate 
P2Y12 expression and potential functional significance in cells other than platelets. 
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